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Abstract
Boron neutron capture therapy (BNCT) is a biologically targeted radiotherapy modality.
So far, 249 cancer patients have received BNCT at the Finnish Research Reactor 1 (FiR 1)
in Finland. The effectiveness and safety of radiotherapy are dependent on the radiation
dose delivered to the tumor and healthy tissues, and on the accuracy of the doses. At FiR
1, patient dose calculations are performed with the Monte Carlo (MC) -based treatment-
planning system (TPS), Simulation Environment for Radiotherapy Applications (SERA).
Initially, BNCT was applied to head and neck cancer, brain tumors, and malignant
melanoma. To evaluate the applicability of the new target tumors for BNCT, calculation
dosimetry studies are needed. So far, clinical BNCT has been performed with the neutrons
from a nuclear reactor, while an accelerator based neutron sources applicable for hospital
operation would be preferable.
In this thesis, BNCT patient dose calculation practice in Finland was evaluated against
reference calculations and experimental data in several cases. Calculations with two TPSs
applied in clinical BNCT were compared. The suitability of the deuterium-deuterium (D-
D) and deuterium-tritium (D-T) fusion reaction-based compact neutron sources for BNCT
were evaluated. In addition, feasibility of BNCT for noninvasive liver tumor treatments
was examined.
The deviation between SERA and the reference calculations was within 4% in the
phantoms studied and in a brain cancer patient model elsewhere, except on the phantom or
skin surface, for the boron, nitrogen, and photon dose components. These dose
components produce 99% of the tumor dose and > 90% of the healthy tissue dose at points
of relevance for treatment at the FiR 1 facility. The reduced voxel cell size ( 0.5 cm) in
the SERA edit mesh improved calculation accuracy on the surface. The erratic biased fast-
neutron run option in SERA led to significant underestimation (up to 30–60%) of the fast-
neutron dose, while more accurate fast-neutron dose calculations without the biased option
are too time-consuming for clinical practice. The SERA calculations for thermal neutron
fluence are also accurate (within 5%) in comparison to the activation foil measurements at
FiR 1. Large (> 5%) deviation was found between the measured and calculated photon
doses, which produces from 25% up to > 50% of the healthy tissue dose at certain depths.
2The MCNP5 code is applicable for ionization chamber response within an accuracy of 2%
 1%, which is sufficient for BNCT. The compact fusion-based neutron generators are
applicable for BNCT treatments, if yields of >1013 neutrons per second could be obtained.
Noninvasive liver BNCT with epithermal neutron beams can deliver high tumor dose
(about 70 Gy (W)) into the shallow depths of the liver, while tumor doses at the deepest
parts  of  the  organ  remains  low  (about  10  Gy  (W)),  if  the  accumulation  of  boron  in  the
tumor compared with that in the healthy liver is sixfold or less.
The patient dose calculation practice is accurate against reference calculation methods for
the major dose components induced by thermal neutrons in the FiR 1 beam. Calculation of
the thermal neutron fluence, which creates the most crucial patient dose, is also accurate
against experimental data. Final verification of the fast neutron and photon dose
calculation is restricted to high levels of uncertainty in existing measurement methods.
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8SYMBOLS AND ABBREVIATIONS
2-D Two-dimensional
3-D Three-dimensional
4-D Four-dimensional
ABNS Accelerator-Based Neutron Source
ANSI/ANS American National Standards Institute/American Nuclear
Society
ASD Aperture-to-Surface-Distance or Aperture-to-Skin-Distance
Au-RR 197Au(n,)198Au activation reaction rate
BAGINS Birmingham Accelerator-Generated epIthermal Neutron
Source
BNCT Boron neutron capture therapy
BNCT_Rtpe BNCT Radiation Treatment-Planning Environment, a Monte
Carlo –based treatment planning software for BNCT
BNL Brookhaven National Laboratory
BPA 10B-boronophenylalanine
BSA Beam-shaping assembly
BSH Sodium borocaptate
BUGLE Broad User Group Library ENDF/B, coupled neutron and
gamma-ray cross-section library
CAVRZnrc User code in EGSnrc software
CBE Compound biological effectiveness factor
C-BENS Cyclotron-Based Epithermal Neutron Source at the Kyoto
University
CH Condensed history (algorithm)
CSDA Continuous slowing down approximation
CT Computed tomography
CTV Clinical target volume
DB Total absorbed dose from boron neutron capture
Dfast Total absorbed dose caused by fast neutrons, mainly recoil
protons from hydrogen
Dg Total absorbed photon dose
DN Total absorbed dose from nitrogen neutron capture
DBCN Debug information card in MCNP
D-D Deuterium-deuterium
DORT A two-dimensional discrete ordinate (deterministic) transport
code
DOSRZnrc User code in EGSnrc software
D-T Deuterium-tritium
E Energy
EGS  Electron Gamma Shower, a Monte Carlo simulation system
EGS4  A Monte Carlo code from the EGS system
EGSnrc  A Monte Carlo code from the EGS system
ENDF  Evaluated nuclear data file, cross-section data library
9EPDL97 Evaluated Photon Data Library 97
ESTEP Parameter on the MCNP material card, that describes the
number of electron substeps per energy step
ETRAN A Monte Carlo transport code for coupled electron-photon
transport
18F-FBPA 4-borono-2 [18F] fluoro-L-phelyalanine
FiR 1 Nuclear research reactor located in Otaniemi, Espoo
FluentalTM Neutron moderator material developed at VTT
FLUKA Fluktuierende kaskade, a Monte Carlo code
FLURZnrc User code in EGSnrc software
GB-10 Polyhedral borane dianion
GEANT4 Geometry  and  tracking  4,  a  toolkit  for  the  Monte  Carlo
simulation of the passage of particles through matter
GTV Gross tumor volume
Gy (W) Weighted Gray
HN Head and neck
HU Hounsfield unit
HVJ Hemaggulutinating virus of Japan
IBA Ion Beam Applications S. A.
IC Ionization chamber
ICRU International Commission on Radiation Units and
Measurements
IND Investigational new drug
INL Idaho National Laboratory
IPPE Institute for Physics and Power Engineering in Obninsk,
Russia
IRDF International reactor dosimetry file, a nuclear cross-section
library
ITS Integrated TIGER series of coupled electron/photon Monte
Carlo transport  codes
JAEA Japan Atomic Energy Agency
JCDS JAEA Computational Dosimetry System
JCDS-FX JCDS based on PHITS code
KERMA Kinetic Energy Released in MAtter by charged particles
KUR Kyoto University Research Reactor
KURRI Kyoto University Research Reactor Institute
LBNL Lawrence Berkeley National Laboratory
L-BPA 4-borono-L-phenylalanine
LET Linear energy transfer
MACLIB Macrolibrary, a nuclear cross-section library
MacNCTPlan Macintosh neutron capture therapy, a MCNP-based treatment
planning software, successor of NCT_plan
McPTRAN.MEDIA A Monte Carlo algorithm based on PTRAN
McPTRAN.CAVITY    A  Monte  Carlo  algorithm  based  on  PTRAN  for  ion  chamber
 calculations
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MIT Massachusetts Institute of Technology
MC Monte Carlo
MCNP General Monte Carlo N-Particle Transport Code
MCNPX Monte Carlo N-Particle Code extended
MCNP5 Version 5 of the MCNP code
MCNP5ITS ITS code based electron energy indexing algorithm in MCNP5
MCNP5new New algorithm for electron energy-loss straggling in MCNP5
MCNP6 A Monte Carlo code based on MCNPX and MCNP5
Mg(Ar) Argon gas-filled ionization chamber with magnesium walls
MLV Multistep Lattice-Voxel
Mn-RR 55Mn(n,)56Mn activation reaction rate
MPM Malignant pleural mesothelioma
MR Magnetic resonance
MRS Magnetic resonance spectroscopy
MultiTrans A three-dimensional simplified spherical harmonics
(deterministic) transport code
NCT_Plan Monte Carlo-based treatment planning code for boron neutron
capture therapy
NCT Neutron capture therapy
NIST National Institute of Standards and Technology
NRI Nuclear Research Institute
PENELOPE  Penetration and Energy Loss of Positrons and Electrons, a Code
 System  for  Monte  Carlo  Simulation  of  Electron  and  Photon
 Transport
PENGEOM  Subroutine  of  PENELOPE  for  modeling  of  geometries  and
materials
PENMAIN A generic main program of PENELOPE
PET Positron emission tomography
PHITS Japanese  Particle  and  Heavy-Ion  Transport  code  System,  a
Monte Carlo code
PMMA Polymethyl-methacrylate plastic
ppm Part per million
PRESTA Parameter Reduced Electron Stepping Algorithm, an electron
transport algorithm in EGS code for ionization chamber
calculations
PSDL Primary standard dosimetric laboratory
PTRAN A Proton Transport Monte Carlo code
PTV Planning target volume
Q value Energy released in nuclear interaction: a difference of energies
of parent and daughter nuclides
R0 Continuous slowing down approximation range of electrons
RBE Relative biological effectiveness
RE Radioembolization
RF Radio frequency
11
RSVPTM Radio Surgery Verification Phantom developed by the
Phantom Laboratory
S() Optional thermal neutron scattering treatment in MCNP,
which accounts the molecular binding effects of hydrogen in
the materials
SBRT Stereotactic body radiation therapy
SERA Simulation Environment for Radiation Applications
seraMC Monte Carlo engine of SERA system
SIRT Selective internal radiation therapy
SPRRZnrc User code in EGSnrc software
TD 5/5 Tolerance dose, 5% probability of complications within five
years
TE(TE) Tissue equivalent ionization chamber
THOR Tsing Hua Open-Pool Reactor in Hsinchu City, Taiwan
THORplan A MCNP-based treatment planning software developed at
National Tsing Hua University in Taiwan
TLD Thermoluminescence dosimeter
TPS Treatment planning system
TRIGA  Training, Research, Isotopes, General Atomics research
reactor type
Univel Uniform-volume element reconstruction method
VTT Technical Research Center of Finland
wi Weighting factor
XCOM Photon Cross-section Database
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1 Introduction
In  radiotherapy,  a  large  dose  of  radiation  is  delivered  to  the  tumor  with  the  aim  of
destroying or damaging the cancer cells, while the dose to the surrounding healthy tissues
is limited to a tolerable level. Conventional external radiotherapy is usually delivered via
high-energy (megavoltage) photons or electrons produced by a linear accelerator. The
effectiveness of the treatment is dependent on the radiation dose delivered to the tumor
location and on the accuracy of the dose. If the dose falls along the steepest region of the
dose-response curves, 5% changes in dose can already result in 1020% changes in tumor
control probability or up to 2030% changes in normal tissue complication probabilities
(Goitein  and  Busse  1975,  Stewart  and  Jackson 1975).  The  International  Commission  on
Radiation Units and Measurements (ICRU) recommends that the radiation dose delivered
should be within 5% of the prescribed dose (ICRU 1978). This means that uncertainty at
each step within the treatment process, including patient positioning, dose planning and
reference dosimetry measurements, should be significantly smaller than 5%. The dose
distribution computed can be considered accurate enough, if it differs from the relative
dose measurements by less than 2% at points of relevance for the treatment (ICRU 1987).
The idea of neutron capture therapy (NCT) is to selectively target the tumor cells by high-
linear  energy  transfer  (high-LET)  heavy  particle  radiation,  which  is  released  when  the
tumor-seeking compound is exposed to an externally applied neutron field (Locher 1936).
In boron neutron capture therapy (BNCT), a 10B containing compound is applied, since
10B has an unusually high thermal neutron (E < 0.4 eV) capture reaction cross-section of
up to 3843 barns (Chadwick et  al. 2006). During neutron irradiation, 10B disintegrates
emitting highly energetic short-range (< 10 m ~ cell diameter) particles, an  particle and
7Li nucleus, via the 10B(n,)7Li reaction (Q = 2.79 MeV). Thermal neutrons have little
effect  on normal cells,  since the capture cross-sections of the major tissue elements 16O,
12C, 1H, and 14N are only 1.9 × 10-4 barns, 3.4 × 10-3 barns, 3.32 × 10-1 barns and 7.5 × 10-2
barns, respectively (Chadwick et al. 2006).
The initial clinical BNCT trials were carried out with the thermal neutron beams on highly
malignant  brain  tumors  in  the  United  States,  at  Brookhaven  National  Laboratory  (BNL,
Upton, NY, USA) and Massachusetts Institute of Technology (MIT, Cambridge, MA,
USA) during the years 1951–1961 (Slatkin 1991). The thermal neutrons penetrated
insufficiently into the deep tumors, damaging the scalp, and the 10B carrier accumulated
inadequately in the tumor cells. Later on, clinical brain tumor trials continued in Japan in
1968 (Nakagawa and Hatanaka 1997). To avoid the thermal neutron penetration problem,
the brain tumors were treated under anesthesia via an open craniotomy procedure and a
new improved compound, sodium borocaptate (BSH) was applied as the 10B carrier
(Hatanaka and Sano 1973). In the 1980s, the melanoma-seeking 10B compound 10B-
boronophenylalanine (BPA) was utilized for intravenous administration in cutaneous and
intracerebral melanoma, combined still with the thermal neutron beams in Japan (Mishima
et al. 1989).
13
In the 1990s, thermal neutrons were substituted with the higher energy epithermal (0.4 eV
<  E  <  10  keV)  neutrons  for  treatments  of  metastatic  subcutaneous  melanoma  of  the
extremities in combination with orally taken BPA at MIT (Madoc-Jones et al. 1996).
During the same decade, clinical BNCT trials were initialized in Europe, combining BSH
and epithermal neutron beams in brain cancer treatments in Petten, The Netherlands
(Hideghéty et al. 1999, Sauerwein et al. 2002). Soon after, BPA and epithermal neutrons
were applied in brain cancer treatments at BNL (Coderre et al. 1997, Chanana et al. 1999),
at MIT (Busse et al. 2003), in Sweden (Henriksson et al. 2008), in Japan (Imahori et al.
1998), and in Finland (Joensuu et al. 2003). Epithermal neutron beams combined with
BPA have also been applied in head and neck (HN) cancer treatments in Japan (Aihara et
al. 2006) and in Finland (Kankaanranta et al. 2007, 2011). In 2003, a clinical cutaneous
melanoma trial was initiated utilizing BPA and a mixed thermal-epithermal neutron beam
in Bariloche, Argentina (Menéndez et al. 2009). In Japan, both current boron carriers,
BPA and BSH,were applied simultaneously with epithermal neutrons in brain tumor and
HN cancer BNCT (Kato et al. 2004, Miyatake et al. 2005, Yamamoto et al. 2008), while
BNCT was combined with conventional fractionated photon radiotherapy in primary
treatment of brain tumors (Matsumura et al. 2009).
The first human liver cancer patients were treated with thermal neutrons in an isolated
liver after surgical removal of the organ from the patient at the research reactor in Pavia,
Italy (Pinelli et al. 2002). Few years later, the first noninvasive liver tumor BNCT was
carried out at Kyoto University Research Reactor (KUR) in Japan: a patient with multiple
inoperable liver tumors received BNCT without surgical procedure, using a newly
developed boron delivery system, intra arterial administration of the boron compound with
a vessel-embolizing agent, lipiodol, in the hepatic arteria (Suzuki et al. 2007). Both BPA
and BSH were used as the 10B carriers and the irradiation was given with an epithermal
neutron beam. Suzuki et al. (2008) also treated the first lung cancer patients, a malignant
pleural mesothelioma (MPM) and another malignant short spindle cell tumor, with BPA-
mediated BNCT.
Originally, BNCT was applied as the last salvage therapy for heavily pretreated HN
patients with recurrent cancer (Aihara et al. 2006, Kankaanranta et al. 2007, 2012).  In
2010, BNCT was successfully applied as the first-line treatment of a large inoperable HN
tumor in combination with intensity-modulated chemoradiotherapy in Finland
(Kankaanranta et al. 2011).
To date, all the clinical BNCT trials have been carried out using reactor-based neutrons
due to the high epithermal neutron flux (about 109 n cm-2 s-1) required. The development
of an accelerator-based neutron source (ABNS), which could be safely installed in a
hospital, has been of interest for almost 3 decades (Barth et al. 1989, Blue and Yanch
2003, Barth and Joensuu 2007, Barth 2009). Development of such ABNSs comprises three
challenging tasks (Blue and Yanch 2003). A high-power accelerator for producing a high-
current charged particle beam is required. An appropriate neutron-producing target needs
to be developed with an efficient heat removal system. A beam-shaping assembly (BSA)
to reduce the initial neutron energy into an optimal epithermal neutron beam needs to be
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designed. So far, the closest to the clinical ABNS for BNCT is the Cyclotron-Based
Epithermal Neutron Source (C-BENS) built at the Kyoto University Research Reactor
Institute (KURRI) in Osaka, Japan by Sumitomo Heavy Industries (Tokyo, Japan)
(Tanaka et al. 2009). C-BENS produces neutrons through the 9Be(p,n)9B reaction,
utilizing the 30 MeV proton beam at 1 mA current. Compact accelerators that produce
neutrons through 2H(d,n)3He (deuterium-deuterium, D-D) or 3H(d,n)4He (deuterium-
tritium, D-T) fusion reaction, developed at the Lawrence Berkeley National Laboratory
(LBNL,  Berkeley,  CA,  USA),  have  also  been  suggested  for  BNCT  use  (Reijonen et al.
2004, 2005).
In  Finland,  clinical  BNCT  trials  were  initiated  by  applying  BPA  as  a 10B carrier and
epithermal neutrons from Finnish Research Reactor 1 (FiR 1, Otaniemi, Espoo, Finland),
in malignant brain cancer patients in 1999 (Joensuu et al. 2003). So far, 249 patients have
been treated with BNCT in 308 sessions, since some patients have received two or three
treatments. Before initializing the clinical trials, the epithermal neutron beam was
reconstructed at the 250 kW FiR 1 Training, Research, Isotopes, General Atomics
(TRIGA) MARK II reactor, the radiobiological studies were carried out, the patient
position system was developed, and the procedures for primary beam dosimetry, treatment
planning, and blood 10B concentration evaluation were established (Auterinen et al. 2001,
Serén et al. 1999, Benczik 2000, Seppälä 2002, Kortesniemi 2002, Ryynänen 2002,
Vähätalo 2004, Savolainen et al. 2012). Later on, complimentary dosimetric methods were
examined (Aschan 1999, Karila 2006, Uusi-Simola 2009).
At  FiR  1,  fission  neutrons  of  up  to  15  MeV  are  slowed  down  to  the  epithermal  energy
range with FluentalTM (69 w-% of AlF3, 30 w-% of metallic Al, 1-w% 7LiF, density about
3 g/cm3) moderator material developed at the VTT Technical Research Center of Finland
(VTT, Finland) (Auterinen et al. 2001). The moderated neutrons are collimated and
gamma-shielded with bismuth into the high-intensity forward-directed (current-to-fluence
ratio 0.77) epithermal neutron beam with low gamma, thermal neutron, and fast neutron
contamination (Seppälä 2002). The FiR 1 beam model was established and verified for
brain cancer patient dose planning in the PhD thesis study by Seppälä (2002). In addition,
a new deterministic three-dimensional (3-D) neutral and charged particle transport code,
MultiTrans, was developed for BNCT dosimetry and dose planning calculations within the
Finnish BNCT project (Kotiluoto et al. 2001, Kotiluoto 2007).
The beam characteristics and intensity were confirmed with the measurements performed
by the Finnish dosimetry team and by visiting teams from the Nuclear Research Institute
(NRI), Rez, Czech Republic (Marek and Viererbl 2004), Idaho National Laboratory (INL),
Idaho  Falls,  ID,  USA  (Nigg et al. 1999a) and MIT, USA (Binns et al. 2005). Neutron
activation foils are used as the primary dosimetry method (Serén et al. 1999, Auterinen et
al. 2004) and the dual ionization chamber (IC) technique as the secondary method (ICRU
1989, Kosunen et al. 1999). The feasibility and accuracy of the dual IC technique were
evaluated in the PhD thesis work by Kosunen (1999). The uncertainties estimated for IC
measurements are not satisfactory and should be improved to be closer to the requirements
of conventional radiotherapy (Kosunen et al. 1999, Uusi-Simola 2009). Particularly, the
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high level of uncertainty (4–20%) in photon dose (Dg) detection increases the uncertainty
of the total patient dose (Seppälä 2002). The applicability of thermoluminescence
dosimeters (TLDs) for detection of Dg was  studied  in  two  works:  in  the  PhD  thesis  by
Aschan (1999) and in the Licentiate thesis by Karila (2006). They concluded that the
absorbed Dg can be measured with the TLDs within 20% in the mixed neutron-photon
field, which enables in vivo measurements with approximately the same accuracy.
Current dosimetric practice was evaluated and complementary dosimeter types, a
microdosimeter and polymer gels, were studied in the PhD thesis by Uusi-Simola (2009).
The microdosimeter provided 10% lower Dg results  than the IC measurements,  but were
roughly within measurement uncertainties, which were rather high (8%). The two gel
dosimeter types studied were found suitable for measuring the relative two-dimensional
(2-D) dose distribution in BNCT.
The dosimetry system was analyzed further and the blood boron concentration estimation
system during the patient treatments, as well as the patient-positioning system, were
developed within the PhD thesis by Kortesniemi (2002). The suitability of the
mathematical models for predicting the kinetic behavior of 10B in the patient during BNCT
treatment  were  evaluated  in  the  PhD  thesis  study  of  Ryynänen  (2002).  In  addition,  two
PhD thesis works were published related to the 10B carrier BPA. In one, 4-borono-L-
phenylalanine (L-BPA) was evaluated for clinical BNCT trials and a radiolabeled
analogue of L-BPA, 4-borono-2[18F]fluoro-L-phenylalanine (18F-FBPA), was developed
for clinical positron emission tomography (PET) imaging studies (Vähätalo 2004). In
another work, the magnetic resonance spectroscopy (MRS) imaging of BPA distribution
in phantoms and in patients was examined (Timonen 2010).
In  addition  to  several  studies  carried  out  in  relation  to  BNCT  dosimetry  in  Finland,
challenges remain in both experimental and computational dosimetry. The dosimetric
methods were investigated in the international Code of Practice in BNCT Dosimetry in
Europe project (Voorbraak and Järvinen 2003) and in intercontinental BNCT dosimetry
exchange collaboration (Binns et al. 2005, Riley et al. 2008). Among the other dosimetric
goals,  one  aim  was  to  define  dimensions  for  the  reference  phantom  used  for  beam
verification and a large scanning phantom used for full characterization of the beam
parameters in the BNCT beams.
To improve the Dg and the total dose detection accuracy with the dual IC method, it has
been suggested that the perturbation effects and relative response of the chambers for the
BNCT beam should be determined through computer simulations of an actual
measurement situation (Munck et al. 2002, Kosunen et al. 1999). Primarily, the Dg
detection accuracy should be improved, since the thermal and epithermal neutrons can be
measured accurately with the activation foils. Modeling of the IC response for photons in
a  neutron  field  requires  transport  of  electrons,  in  addition  to  neutrons  and  photons.  An
accurate simulation of the chamber response is a challenging task for the simulation codes,
since it requires correct modeling of boundary crossing of electrons between media of
highly different densities and electron backscatter from the chamber walls. Few codes that
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have been verified for chamber response simulations at clinically required accuracy are
not able to simulate neutron transport, whereas a coupled neutron-photon-electron
transport code Monte Carlo N-Particle (MCNP) (Briesmeister 2000) utilized in BNCT
dosimetry, has not been verified for the IC response simulations.
So far, beam characterization measurements and calculations have been performed in
regular cylindrical or cubical phantoms with the flat ends attached to the beam port. This
set up has been a valid verification method for treatments of regular targets, such as the
brain. However, near the curvature boundary regions, discrepancy between the calculated
and the measured dose is potentially greater. Therefore, verification of the measurements
and calculations with more realistic anthropomorphic phantoms is recommended, when
the treatments are extended from the brain to the HN area or elsewhere in the body
(Kortesniemi 2004).
The treatment planning systems (TPSs) used currently in Finnish clinical trials
miscalculates the dose near the surfaces of two very different densities, such as air or bone
and soft tissue (Seppälä et al. 2002, Seppälä 2002). It has been suggested that reliability of
the dose calculation could be enhanced if smaller voxel cells were applied in calculation
edit mesh near the boundary regions (Seppälä 2002).
Each epithermal neutron beam applied for BNCT worldwide is unique and various dose-
determining methods are available. Intercomparison measurements have shown that
systematic differences of up to 10% are obtained between different institutes in
determining the biologically weighted BNCT dose (Binns et al. 2005, Uusi-Simola 2009).
To compare the clinical outcomes between the institutes, comparison of the beam
parameters, applied dosimetry methods and the TPSs are necessary.
This thesis focuses on BNCT dosimetric studies, using Monte Carlo (MC) simulations. In
the first part of the thesis, the computer simulations and main dosimetric methods used in
external beam therapy are introduced. Afterwards, the dosimetric methods and simulation
codes applied in BNCT, as well as neutron sources and target tumors suggested for
BNCT, are summarized. Finally, six publications included in this thesis are reviewed with
some unpublished additional data, and the conclusions and discussions of the study
outcomes are provided.
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2 Aims of the study
The aims of this thesis were, using MC simulations, to evaluate existing patient dose
calculation practices applied in Finnish clinical BNCT trials against reference dose
calculation methods and measurements, to establish new dosimetric methods for more
accurate dose determination, and to evaluate the suitability of the compact accelerator-
based neutron sources for BNCT. The specific aims were:
1. To determine the dimensions of a dosimetric reference phantom for neutron beam
calibrations and a large water-scanning phantom for full characterization of the beam
parameters (Publication I) and to evaluate the suitability of the MCNP code version 5 for
IC response simulations (Publication VI).
2. To evaluate the dose calculations with the BNCT TPS in comparison to other dose
calculation methods or measurements in different phantom geometries (Publication II and
Publication IV), by comparing the cross-section libraries in function of neutron energy
(Publication II), with different treatment distances (Publication IV), and in brain cancer
patient treatment (Publication III).
3. To determine the applicability of accelerator-based fusion neutrons for BNCT
treatments and the feasibility of treating liver tumors with external beam BNCT
(Publication V).
In addition to the data published in the Publications I-VI, some previously unpublished
simulation results are presented in Sections 6.1, 6.2, 7.2, and 8.1 of this thesis.
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3 BACKGROUND
3.1 Computer applications in medical physics
Computer applications were originally developed to give faster and more accurate results
in medical dosimetric problems that were at first handled by manual methods. Later on,
computer techniques have been used more extensively and have enabled the solving of
new problems, that could not have been considered without the aid of computers. The
range of MC applications is very wide in medical physics (Rogers 2006). Computer
simulations are used e.g. in TPSs for external beam radiotherapy, in photodynamic
therapy, in nuclear medicine imaging, diagnostic X-ray applications, brachytherapy, in
calculation of radiation protection quantities, and in modeling radiation detector response.
This thesis focuses on computer simulation-based dose calculation in radiotherapy.
3.2 External beam therapy
3.2.1 Reference dosimetry
The purpose of clinical dosimetry is beam calibration and verification of the dose planning
calculations. Current clinical dosimetry of external beam radiation therapy is based on
determination of the absorbed dose to water, since it relates closely to the biological
effects of radiation in tissue. Three basic dosimeters that are accurate enough for primary
standard are the calorimeter, chemical dosimetry, and IC (ICRU 2001, Andreo et al.
2000).  The  ICs  are  usually  applied  at  hospitals,  since  they  are  the  most  easily  used
instruments (Carrier and Cormack 1995). A cylindrical IC type may be used for the
calibration of radiotherapy beams of medium-energy (above 80 kV) X-rays, 60Co gamma
beams, high-energy (MeV scale) photon beams, electron beams with energy above 10
MeV, and therapeutic proton and heavy-ion beams. The plane-parallel chambers are
recommended for all electron energies and below 10 MeV their use is mandatory (Andreo
et al. 2000).
Primary standard dosimetric laboratories (PSDLs) determine the absorbed dose to water,
using water calorimeters, and provide calibration factors for the ICs in terms of absorbed
dose to water for use in radiotherapy beams (Andreo et al. 2000). The reference
conditions, which affect the absorbed dose measurement, are the geometrical
arrangements such as distance from the radiation source to the detector and to the phantom
surface, measurement depth in the phantom, phantom size and material, radiation field
size, dose rate, and the ambient temperature, pressure, and relative humidity. The
calibration measurements are typically performed under full-scattering conditions at the
reference depth in a reference phantom. The reference medium recommended for electron
and photon measurements is liquid water, whereas solid phantoms in slab form may be
used for low-energy electron beams and are recommended for low-energy X-ray
dosimetry (Andreo et al. 2000). The dose determination must always be referred to the
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absorbed dose to water at the reference depth in  a  liquid  water  phantom (Andreo et al.
2000). The reference phantom size must extend to at  least  5 cm beyond all  four sides of
the largest field size determined at the measurement depth and there should be a margin of
at least 5 g/cm2 (10 g/cm2 for medium-energy X rays) beyond the maximum measurement
depth (Andreo et al. 2000). The reference depth is on the beam axis in the phantom at the
depth at which full backscattering is achieved. Typically, for a high-energy electron or
photon beam, the reference measurement depth is at 5 g/cm or at 10 g/cm (Andreo et al.
2000).
3.2.2 Dose planning
Computerized radiotherapy TPSs are used in external beam radiotherapy to generate
radiation beam shapes and dose distribution within the patient. For dose planning, the
patient is imaged with computed tomography (CT) and often also with magnetic resonance
(MR) or PET scanners. The medical images are used to determine the gross tumor volume
(GTV) (ICRU 1993), often defined according to images taken before tumor resection, and
clinical target volume (CTV), which contains GTV and subclinical microscopic
malignancies to be treated adequately (ICRU 1993). The planning target volume (PTV)
includes CTV and the surrounding margin, which is added to take into account all possible
geometrical variations and inaccuracies to ensure delivery of the prescribed dose in the
CTV (ICRU 1993). The CT images of the patient not only illustrate the locations of the
PTV and healthy tissues, but also contain data on the tissues’ electron density matrix,
which can be utilized in dose distribution calculations in photon and electron beam
therapy (Schneider et al. 1996). The dose planning determines the number, orientation,
type, and characteristics (size and shape) of the radiation beams needed to deliver the
desired radiation dose to the PTV, while dose to the surrounding healthy tissues remains at
a  tolerable  level.  The  dose  planning  process  consists  of  beam  data  acquisition  from  the
measurements and entry into the TPS, patient anatomical data acquisition from the
medical images, dose calculation, and the final transfer of data to the treatment machine.
The beam data are acquired from the measurements in the reference condition. The
reference condition is a beam, usually defined by a square aperture, directed at the surface
of the reference phantom (ICRU 1987). Currently, 3-D image-based dose planning is the
most common practice in the clinics. Recently, four-dimensional (4-D) image-based dose
planning has also been used (Simpson et al. 2009).
In  the  current  algorithms,  the  radiation  beam  data  are  decomposed  into  primary  and
secondary radiation components and are handled independently. In this way, changes in
scattering due to beam shape, beam intensity, patient geometry, and tissue heterogeneities
are taken into account in the dose distribution (IAEA 2005). The dose deposited by the
photons can be calculated from the total photon-energy fluence distribution within the
medium. The fluence distribution can be presented mathematically with the Boltzmann
transport equation, which mathematically describes particle transport through the host
medium (Duderstadt and Martin 1979). In current clinical applications, the Boltzmann
equation is usually solved, using radiation kernels based on either convolution or
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superposition methods. The kernel superposition methods are either point spread functions
or pencil beams (ICRU 1987, Tillikainen et al. 2008). A weakness of kernel approaches is
that they are only valid at points within the media at which charged particle equilibrium is
reached in photon and electron beams. Disequilibrium of electrons exists near the
interfaces between materials of highly differing densities such as lung, bone, and air.
An accurate method for solving the particle transport equation in full patient geometry is
using either stochastic or deterministic methods. Rapid deterministic methods, such as the
discrete ordinate method, are not currently available for clinical use (Gifford et al. 2006,
Wareing et al. 2007, Kotiluoto et al. 2001). The MC method is stochastic and thus does
not solve the Boltzmann transport equation numerically, but simulates a particle’s
probable behavior within the medium, using statistical sampling. MC methods are very
accurate in complex treatment geometries and in cases of tissue heterogeneities, but are
time-consuming, since a huge number of particles needs to be simulated to achieve results
with  low statistical  uncertainty.  Until  recent  times,  MC methods  have  been  too  slow for
routine clinical use (Chetty et al. 2007). Fast MC calculations often require utilizing
variance reduction techniques and efficiency-enhancing methods (Kawrakow and Fippel
2000). Such fast MC algorithms have enabled clinical MC-based dose planning and are
being implemented in various widely used commercial TPSs (Fragoso et al. 2010,
Grofsmid et al. 2010, Heath et al. 2004, Künzler et al. 2008, Leal et al. 2003).
Currently, MC methods are considered the most accurate way to determine the dose in
radiotherapy (Rogers 2006). These methods are used e.g. for determining beam parameters
(energy deposition kernels) for radiotherapy dose planning and calculation of dosimetric
parameters, such as water-to-air stoppingpower ratios and a variety of correction factors
for IC measurements (Verhaegen and Seuntjens 2003, Chetty et al. 2007, Rogers et al.
2006).
3.2.3 Ionization chamber response simulations
The simulation of IC responses has been considered one of the most difficult calculation
problems for MC codes (Nahum 1988, Kawrakow 2000, Rogers 2006). The code must
correctly simulate electron transport through a gas-solid interface and electron backscatter
from the chamber walls. In case of a neutron or charged particle beam, chamber response
simulation  also  requires  accurate  transport  of  neutrons  and  often  other  charged  particles
initiated within the measurement geometry by neutrons.
Explicit simulation of electron transport interaction by interaction is often not feasible in
practice, since an electron undergoes a huge number of small interactions during its
lifetime. Electron transport simulations are usually solved with condensed history (CH)
algorithms (Berger 1963). In CH algorithms, the cumulative effect of multiple collisions is
condensed into a single “step” of electron path length, instead of modeling every
interaction. This can be done, since most of the single collisions between electrons and
atoms occur very closely together and result in very small changes in direction and energy
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loss. During each CH step, angular scattering and energy loss processes of the particle
transport equation are sampled from probability distributions based on multiple-scattering
theories. For the multiple-scattering theories to be valid, the electron steps need to be long
enough to represent many collisions, but short enough that the mean energy loss during
each step is small.
Invention of the CH algorithm enabled the MC simulation of charged particle transport
(Kawrakow 2000). In the class I CH algorithm, all collisions are simulated in the
predetermined energy grid. One disadvantage of the algorithm is that most of the electron
steps correspond to an energy that does not equal any of the grid energies and
interpolations are needed. Another disadvantage is that the energy and direction of the
primary particle are not affected by the secondary particles created along its path and
therefore energy and momentum are not conserved in a single interaction. In the class II
CH  algorithm,  all  the  interactions  are  divided  into  hard  and  soft  collisions.  The  soft
collisions are treated as in the class I approach, while the hard collisions (inelastic
collisions above a certain threshold energy of the secondary electrons) are simulated
explicitly collision by collision. The class I approach is used to describe multiple
scattering and the class II approach to simulate radiative energy loss in the electron
transport MC codes Couple Electron-Photon Transport (ETRAN) (Berger 1963, Seltzer
1988, 1991), Integrated Tiger Series (ITS) (Halbleib et al. 1992), MCNP (Briesmeister
2000), Geometry and Tracking 4 (GEANT4), (Agostinelli et al. 2003, Carrier et al. 2004)
and Electron Gamma Shower (EGS) based codes (Nelson et al. 1985, Kawrakow and
Rogers 2003, Kawrakow 2000a, Kawrakow 2000b). EGS4, EGSnrc, and GEANT4
employ the class II approach also to simulate collisional energy loss. Penetration and
Energy Loss of Positrons and Electrons (PENELOPE) (Sempau et al. 1997, Salvat et al.
2006) implements the class II scheme for all electron interactions.
The  first  MC code  able  to  simulate  the  IC response  at  the  0.1% level  of  accuracy  (with
respect to its own cross-sections) was EGSnrc (Kawrakow 2000a, 2000b). The precursor
of the code, EGS4 and specially its Parameter Reduced Electron Stepping Algorithm
(PRESTA), showed strong electron step size dependence of the calculated dose in a small
low-density cavity (Rogers 1993). Thus the EGSnrc code was specially tailored for
accurate IC response and electron-backscattering simulations by implementing various
new algorithms in the code: a new any-angle multiple elastic-scattering theory, an
improved electron step algorithm, a correct cross-section method for sampling distances
between discrete interactions, a more accurate evaluation of energy loss, and an exact
boundary-crossing algorithm (Kawrakow 2000a, 2000b). The EGSnrc code has been used
extensively in determination of a wide variety of correction factors in radiation dosimetry
(Mainegra-Hing et al. 2003, Capote et al. 2004, La Russa and Rogers 2006, La Russa et
al. 2007, Wang and Rogers 2007, 2008a, 2008b). By definition, a more recent MC code,
PENELOPE, is also an accurate tool for IC response simulations, since the boundary-
crossing artifacts are avoided in the code (the surface-limiting scoring regions are not real
boundaries) and electron transport can be performed fully explicitly (Salvat et al. 2003).
Consequently, PENELOPE has provided IC response results within 0.2% from the
analogue simulation of the same problem (Sempau and Andreo 2006). Neither the EGSnrc
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nor the PENELOPE code is able to handle neutron transport, and thus for the IC response
simulations in the neutron or charged particle beams, another code needs to be applied.
The IC response simulations in the proton or heavy ion beam have been solved by
applying an analytical model or the MC codes Fluktuierende Kaskade (FLUKA) (Kirby et
a.l 2010), Proton Transport (PTRAN) (Berger 1993) or its MC algorithms
McPTRAN.MEDIA and McPTRAN.CAVITY (Palmans 2004 and 2006, Palmans et al.
2002). The McPTRAN.MEDIA and McPTRAN.CAVITY are based on the transport
algorithm of PTRAN that simulates proton pencil beams in homogenous water.
3.3 BNCT
3.3.1 Neutron sources
The optimum neutron beam energy for treating deep-seated tumors with BNCT is from the
4 eV to 40 keV energy spectrum peaking at 10 keV (Yanch et al. 1991). Since the most
penetrating neutron beam can be easily moderated further to be less penetrating if needed,
e. g. by placing a tissue-equivalent (TE) material on the patient’s skin (Seppälä et al.
2004), the most penetrating neutron beam can be considered the optimum and the most
usable  for  BNCT  treatments  of  different  tumor  types.  To  date,  all  clinical  BNCT  trials
have been carried out using reactor-based neutrons due to the high neutron flux required,
while there is urgent need for hospital-based neutron sources (Barth and Joensuu 2007).
The development of ABNSs, which could be safely installed at the hospital, has been of
interest for almost three decades (Barth et al. 1989, Wang et al. 1990, Yanch et al. 1992,
Barth 2009). Many different neutron-producing reactions could be exploited with an
accelerator. The neutron-producing reactions are induced by accelerated protons,
deuterons, or tritons targeting 7Li, 9Be, 13C, 12C, 2H, or 3H nuclei, via the reactions listed in
Table 1.
Table 1 Characteristics of charged particle reactions considered for acceleralor-based BNCT.
The data were obtained from Bleuel (2003), Blue and Yanch (2003), and Tanaka et al. (2009).
Reaction Bombarding
energy
(MeV)
Average neutron
energy
(MeV)
Maximum neutron
energy
(MeV)
Neutron
production rate
(n mA-1 s-1)
7Li(p,n)7Be 2.5 0.55 0.79 9.1 × 1011
9Be(p,n)9B 4.0 1.06 2.12 1.0 × 1012
9Be(p,n)9B 30 28 1.9 × 1014
9Be(d,n)10B 1.5 2.01 5.81 3.3 ×1011
13C(d,n)14N 1.5 1.08 6.77 1.9 × 1011
2H(d,n)3He 0.15 2.5 2.5 4.7 × 108
3H(d,n)3He 0.15 14.1 14.1 5.0 × 1010
Probably, the most studied ABNS application is the 7Li(p,n)7Be reaction at approximately
2.5 MeV proton energy, because sufficiently low accelerator current (10 mA) is needed
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for producing a high intensity of reasonably low-energetic neutrons (up to 1 MeV). Such
BNCT beams with functional lithium target and BSA have been built at the University of
Birmingham in the UK (Culbertson et al. 2004) and at the Institute for Physics and Power
Engineering (IPPE) in Obninsk, Russia (Kononov et al. 2004). However, the neutron
yields of these accelerator devices do not reach the reactor-based neutron beam intensity,
probably because these accelerators were not originally designed for BNCT application.
For the Birmingham Accelerator-Generated epIthermal Neutron Source (BAGINS,
University of Birmingham, Birmingham, UK), the beam parameters measured are 17%
lower than expected theoretically for the 1 mA proton beam at a potential of 2.8 MV, due
to  poor  proton  beam  collimation,  causing  part  of  the  proton  beam  to  miss  the  Li  target
(Culbertson et al. 2004). In addition, there was an attempt by Ion Beam Applications S. A.
(IBA,  Louvain-La-Neuve,  Belgium)  to  build  a 7Li(p,n)7Be reaction-based accelerator
device for BNCT (Forton et al. 2009). The accelerator was built to operate with a 20 mA
proton beam current at 2.5 MeV, whereasthe  measured neutron production data for the
device have not been published.
A common problem for all  neutron sources in BNCT is that, in contrast to other beam
therapies (e.g. proton, fast neutron, photon, or electron sources), considerable moderation
of the source neutrons is usually required, since the efficient ways of producing neutrons
usually  yields  neutrons  of  high  energy  (>  0.7  MeV).  The  only  way  to  slow  these  high-
energy neutrons down is through nuclear interactions, and thus during the moderation,
neutron intensity is reduced by about four orders of magnitude. Consequently, the BNCT
neutron source needs to be operated at considerably higher power than a proton therapy
accelerator. For example, the 7Li(p,n)7Be neutron source with 2.5 MeV protons requires
20 mA current for BNCT, whereas a typical proton therapy unit with proton energy up to
250 MeV operates at approximately 500 nA current. The high-intensity neutron source
results in strong activation of the materials within the device. The higher the proton (and
resulting neutron) energy the more likely that elements near the accelerator and within the
BSA get activated. The binding energy of all nuclides found in nature is from 1.1 MeV to
8.8 MeV. At energies above 8.8 MeV, every possible element becomes activated. Thus,
lower proton beam energy would be preferable in practice. In addition, difficulties in
reducing the fast neutron and photon components from the clinical neutron beam are
experienced (Tsukamoto et al. 2011), if high (up to 30 MeV) initial neutron energy is
utilized.
A compact neutron source based on 2H(d,n)3He (D-D) or 3H(d,n)4He (D-T) fusion
reactions yielding 2.45 MeV and 14.1 MeV neutrons, respectively, has been suggested for
BNCT use (Verbeke et al. 2000, Cerullo et al. 2004, Publication V, Reijonen et al. 2005,
Durisi et al. 2007). These reactions have positive Q values and thus, low bombarding
energy is required in comparison to the other neutron-producing reactions. The fusion
neutron source is compact in size and also safe for hospital use. The fusion-based neutron
sources are commercially available. Such neutron sources used to be very common in
neutron research facilities and at universities, and thus, the technology required is well
known. For clinical BNCT, the yield required with D-D fusion neutrons is estimated to be
on the order of 1012 neutrons per second and with the D-T fusion neutrons 1013 neutrons
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per second (Reijonen et al. 2005). The neutron yield of commercially available fusion
neutron sources is usually a maximum of about 108 neutrons per second.
The Plasma and Ion Source Technology group, team at the Ion Beam Technology Group,
at LBNL has developed high-current D-D fusion neutron generators for various
applications with neutron yields up to 1011 neutrons per second. The generators are of
various designs, but all are operated with radio-frequency (RF) induction discharge, which
ensures high efficiency and long lifetime (Reijonen et al. 2005). Basically, RF induction
generates the deuterium plasma in the discharge chamber, usually with an external
antenna. An advantage of RF induction discharge is its ability to generate high fractions of
atomic ions from molecular gases and to generate high plasma densities for high
extractable ion currents from relatively small discharge volumes (Reijonen et al. 2004).
The RF discharge has demonstrated ion species nearly mono atomic. In the accelerator
part of the generator, the ions are accelerated from the source to impinge on a metallic,
usually titanic, target with voltages of about 120 kV or above. The ion beam self-loads the
target surface with H+ ions where the fusion reaction occurs. At an energy of 120 keV, the
2H(d,n)3He fusion reaction cross-section is already sufficiently high, while it further
increases up to 2.4 MeV, as shown in Figure 1. The 3H(d,n)4He fusion reaction cross-
section peaks at about 120 keV, which is clearly a favorable voltage for D-T neutron
production. The D-T fusion reaction cross-section is about 200 times that of the D-D
fusion reaction, and so the same ion beam current and voltage with D-T fusion provides
200 times higher neutron yield. The most powerful compact D-D neutron generator
developed at LBNL is designed to operate with a 330 mA 2H ion current and 120 kV
acceleration voltage providing about 1011 neutrons per second (Reijonen et al. 2005). The
same neutron generator is aimed to run with mixed 2H and 3H gas to yield about 1013 D-T
fusion neutrons per second.
Figure 1 2H(d,n)3He (D-D) and 3H(d,n)3He (D-T) fusion reaction cross-sections plotted according
to ENDF-B/VII.0 library data (Chadwick et al. 2006).
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3.3.2 Target tumors
In theory, some tumors are resistant to low-LET radiation. Some has suggested that high-
LET radiation may offer a biological advantage in these tumors, since high-LET particle-
induced cell killing is less dependent on oxygen levels than cell killing by low-LET beams
(Warenius et al. 2000). In addition, high-LET radiation is densely ionizing and repair of
potentially lethal damage occurs less frequently in cancer cells after high-LET irradiation
(Gragg et al. 1977). In radiation-resistant tumors, the cells undergo slow cycling and are
redistributed poorly, and the cell cycles are dominated by cells in resistant phases (Griffin
and Phillips 1997). Radiation-resistant tumors include melanoma, sarcoma of the bone and
soft tissues, adenocarcinoma of the thyroid, respiratory system, and alimentary systems
and peripheral nerve tumors, such as gliomas.
As a source of high-LET radiation, BNCT has been used to treat radiation-resistant
tumors. In the early days, BNCT was applied to high-grade gliomas and malignant
inoperable melanoma in the brain and extremities. Due to the high gradient between
healthy tissue dose and tumor dose, it has been possible to apply BNCT to recurrent
tumors in patients who have previously received full dose of conventional radiation
therapy. Later on, other brain tumors such as malignant recurrent inoperable meningiomas
have also been natural candidates for BNCT due to extensive early research on BNCT
effects on brain tissue (Miyatake et al. 2006). Lately, large recurrent inoperable HN
tumors, including thyroid and oral cancer, have been treated with BNCT (Kouri et al.
2004, Kato et al. 2004, Kankaanranta et al. 2007, Kankaanranta et al. 2011). Since the
prognosis in MPM is dismal, lung cancer has been of interest among BNCT researchers
(Suzuki et al. 2006 and 2008, Protti et al. 2009, Bortolussi et al. 2010) and the first
patients have been treated in Japan (Suzuki et al. 2007).
The liver is the most common target of metastases from many primary tumors (e.g.
colorectal cancer, breast, lung, etc. (Vitale et al. 1986). The response rate for inoperable
liver tumors to traditional radiation treatment or chemotherapy is poor, while surgical
resection of limited metastatic liver tumors is effective in selected patient groups
(Nordlinger et al. 1978, Fong et al. 1997, Singletary et al. 2003). With conventional
techniques, radiation therapy for liver was not considered meaningful, since the tolerance
dose (TD 5/5, 5% probability of complications within five years) is only 30 Gy for
fractionated (from 1.8 to 2 Gy dose per day) whole liver irradiation (Emami et al. 1991).
However,  development  of  stereotactic  body  radiation  therapy  (SBRT)  has  enabled
investigations of radiotherapy of selected liver metastases, since the SBRT method allows
delivery of high radiation doses precisely focused on the target. Either a single dose or a
small number of fractions has been utilized in liver tumor SBRT (Herfarth et al. 2004,
Blomgren et al. 1995, Timmerman et al. 2003, Schefter et al. 2005). In SBRT studies, the
mean doses to healthy liver remain low (maximum of 24 Gy), even in the highest dose
group (Schefter et al. 2005). The high-dose study (60 Gy in three fractions) required that
700 ml of normal liver should receive less than 15 Gy and reported high (92%) local
control rate at 2 years with mild acute toxicity (Rusthoven et al. 2009).
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Previous clinical BNCT studies indicate that whole-liver BNCT could be an effective way
to destroy liver metastases (Pinelli et al. 2002, Zonta et al. 2009). The first human liver
cancer patient was treated with thermal neutrons in a liver with several adenocarcinoma
metastases removed surgically from the patient (Pinelli et al. 2002). Due to the high
concentration ratio between tumor and healthy cells (6:1) and their different responses to
high-LET radiation, much higher boron dose (DB) in the tumor than in healthy liver cells
were delivered. However, due to the complexity of surgical removal of the liver and its
high risks of complications, noninvasive BNCT given without removing the liver from the
body  may  be  preferable,  if  low  dose  to  healthy  tissue  and  sufficient  tumor  dose  can  be
assured.
During recent decades, another new innovative targeting radiotherapy modality,
radioembolization (RE) with yttrium-90 microspheres, often called selective internal
radiation therapy (SIRT), has been introduced for liver cancer treatments (Dancey et al.
2000, Sarfaraz et al. 2003). The idea of SIRT is to deliver radioactive 90Y isotope-
containing microspheres directly into the tumor via the hepatic arteria, which is possible
since the tumors are often more vascular than the normal liver (Dancey et al. 2000). In
SIRT, it is possible to deliver high radiation doses up to >1000 Gy selectively in the
tumor, while sparing healthy surrounding liver tissue (Dancey et al. 2000, Sarfaraz et al.
2003 and 2004, Stubbs et al. 2001).  Nonetheless,  while  high  tumor  response  rates  have
been reported, SIRT is a still palliative treatment modality (Prompers et al. 2011).
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4. Overview of BNCT dosimetry
4.1 Dose components
An incident BNCT beam consists of neutrons and photons with wide energy spectra. Four
distinct dose components with different biological effects are important when the beam
enters tissue: the Dg, fast neutron dose (Dfast), nitrogen dose (DN), and DB (IAEA 2001).
These dose components must be quantified, using special dosimetry procedures. The Dg
consists of two components, primary photons initiated from the reactor core and BSA
structures and secondary photons from the nuclear reactions within the tissue. The Dfast is
primarily caused by fast but also epithermal neutrons through the 1H(n,n’)p reaction in
tissue (also called the hydrogen dose or proton recoil dose). The DN consists of a locally
deposited dose from emitted protons and recoiling 14C nuclei from the thermal neutron
absorption reaction 14N(n,p)14C in tissue. The DB consists of high-energy  and 7Li
particles. In 94% of the 10B(n,)7Li reactions, 477 keV gamma rays are emitted, which are
ignored in dosimetric evaluation, because they are about two orders of magnitude less
significant than the gamma rays from the hydrogen capture reaction, although these
characteristic gammas are utilized for 10B analysis purposes.
All  of  the  dose  components  have  their  own relative biological effectiveness (RBE), and
thus, to compare the BNCT dose with the fractionated absorbed dose in photon
radiotherapy, each dose component needs to be multiplied with the weighting factor (wi).
Using wi, the total weighted absorbed dose in photon dose equivalent units, weighted Gray
(Gy (W)), can be defined as follows (Bleuel et al. 1998, Savolainen et al. 2001, Seppälä et
al. 2001):
DW  wgDg 	 wB DB 	 wN DN 	 w fastDfast
The  wi are energy- and dose rate-dependent and thus, are also dependent on individual
beam characteristics and scattering conditions (location in the body or in the phantom). In
addition, the biological effectiveness is dependent on the tissue. Moreover, synergy
between the various radiation components is indicated, which results in a greater
biological effect than would be in the case of independent action of the various radiation
types (Phoenix et al. 2009). Nonetheless, constant values for the wi values of 1 for Dg
 and
3.2 for Dfast and DN are commonly applied, regardless of the tissue (Coderre and Morris
1999, Seppälä 2002).
Dfast and DN are dependent on the hydrogen and nitrogen mass fraction and the mass
density of the tissue. Most commonly, elemental compositions of tissues are defined
according to ICRU Report 46 (ICRU, 1992), while in Finnish clinical protocol, the
hydrogen and nitrogen compositions of the brain are defined according to Brooks et al.
(1980) (10.6 mass-% of hydrogen and 1.84 mass-% of nitrogen), as in the Brookhaven
clinical trials (Chanana et al. 1999, Seppälä 2002). In Finland, neutron transport is
performed through ICRU-based tissues, but the difference in the hydrogen and nitrogen
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mass fraction between the Brookhaven brain and the ICRU based brain is taken into
account in the corresponding wi values (Seppälä et al. 2001).
The wi for DB is called the compound biological effectiveness factor (CBE), since it is not
only dependent on the radiosensitivity of the tissue, but also on the boron carrier applied.
The CBE factors of 1.3, 3.8, and 2.5 for BPA in brain, tumor, and skin, respectively, are
recommended (Coderre and Morris 1999) and applied in the Finnish clinical protocols
(Seppälä 2002).
For calculation of the physical DB, the boron concentration of tissue needs to be evaluated.
The boron concentration of blood during neutron irradiation has been from about 11 parts
per million (ppm) to 30 ppm, depending on the BPA infusion dose in the clinical BNCT
trials in Finland (Kankaanranta et al. 2007, 2011, 2012).
4.2 Phantoms
BNCT dosimetry is performed in air to characterize the neutron beam and in the phantom
to calibrate the beam model and normalize and verify the computational treatment
planning. At the FiR 1 reactor, the dose planning normalization and validation are
performed in a cylindrical phantom with dimensions (diameter 20 cm, length 24 cm)
similar to those of the human head, because the clinical trials have been focused on the
brain and HN tumor treatments. A solid polymethyl-methacrylate (PMMA) plastic
phantom is used for dose planning normalization and a water-filled phantom for validation
(Seppälä 2002). The dose planning normalization measurement is performed at the
reference depth, which is located 2 cm deep along the central beam axis in the phantom
for the FiR 1 beam, wherein the thermal neutron fluence maximum is reached. The solid
plastic was chosen as the phantom material for beam normalization, instead of water, for
more exact detector (activation foil) positioning and practicality, while water simulates
BNCT doses in brain tissue better than PMMA (Seppälä 2002, Seppälä et al. 1999). Water
is a suitable phantom material for dosimetry of epithermal neutron beams, since it is
practical and provides scattering conditions similar to those of tissue (Seppälä et al. 1999,
Raaijmakers et al. 1995, Wojnecki and Green 2001).
In dosimetry of external radiotherapy, the beam calibration measurements are typically
performed under full scattering conditions at the reference point in a reference phantom.
Full characterization of the dose components for beam model verifications in dosimetric
and dose planning calculations must be performed in a scanning phantom, which is
sufficiently large to approximate an infinite scattering medium at each measurement point.
The reference phantoms or the large scanning phantoms recommended for photon,
electron, fast neutron, and heavy ion therapy cannot be adopted directly in BNCT
dosimetry,  due  to  very  different  scattering  and  attenuation  characteristics.  To  define  the
reference and scanning phantom dimensions for BNCT, each of the dose components
needs to be considered separately, since they have independent spatial distributions. In
Publication I, the minimum dimensions of a reference phantom and a large scanning
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phantom were determined for beam calibration and neutron source characterization
measurements at FiR 1. The study was performed as part of the Code of Practice in BNCT
Dosimetry in Europe project (Voorbraak and Järvinen 2003).
The  large  homogenous  phantoms  are  geometrically  very  unlike  the  patient,  and  thus
anatomical phantoms have been applied for geometric considerations of the beam
parameters. Water-filled Snyder (Snyder et al. 1969) or other similar ellipsoidal head
phantoms have been used for comparisons of measurements and calculations (Kortesniemi
2002), to compare the treatment planning codes (Wojnecki and Green 2002, Goorley et al.
2002), or to study the BNCT beam parameters during beam optimization (Bleuel et al.
1998). The Snyder head phantom with anatomical structures (skin, skull, brain and
possibly tumor) has been used to test the important aspects of the treatment planning
codes such as dose volume calculations and calculation accuracy near material boundaries
(Goorley et al. 2002, Albritton and Kiger 2006, Durisi et al. 2009).
In brain tumor BNCT, a beam aperture-to-skin surface distance (ASD) of nearly zero
centimeters has been applied, and thus most phantom studies have been performed with
the phantom attached to the beam aperture. However, for treatment of tumors located in
the  other  parts  of  the  body,  increased  ASD  may  be  required.  Although  the  beams  are
usually forward-directed at the beam aperture plane (at FiR 1, neutron current-to-flux ratio
0.77), changes in the ASD may lead to changes in the patient dose distribution. An
irregular surface shape (face structures and jawline) also influences the dose distribution in
typical HN cancer treatment, and thus validation of dose planning in the anthropomorphic
phantoms is essential.
4.3 Primary dosimetry: activation foil technique
The DB and DN are not measured directly, but are calculated from the thermal neutron
fluence measured with the neutron activation technique. At the FiR 1 facility, the thermal
neutron and epithermal neutron fluence are determined through the 55Mn(n,)56Mn and
197Au(n,)198Au activation reaction rates (RR) (denoted from here on as Mn-RR and Au-
RR, respectively) measurements with diluted Mn-Al and Au-Al foils (1 w-% of Mn and
Au, respectively) (Nigg et al. 1999a, Seppälä 2002, Voorbraak and Järvinen 2003). The
uncertainty of the Mn-RR and Au-RR measurements is only 3% (Seppälä 2002, Serén et
al. 1999). Au-RR is used to normalize the beam model in a phantom, since the uncertainty
of the 197Au(n,)198Au  reaction  cross-section  is  very  low  (<  1%)  in  comparison  to  the
55Mn(n,)56Mn reaction cross-section (< 4.5%) at the energy range of interest in BNCT
(Seppälä 2002). The Dfast can be determined from the fast neutron fluence characterized
via 115In(n,n’) (threshold 430 keV), 27Al(n,)24Na (threshold 6.5 MeV), 54Fe(n,p)54Mn
(threshold 800 keV), or 58Ni(n,p)58Co (threshold 1.9 MeV) activation reaction
measurements (Serén et al. 1999, Auterinen et al. 2004b, Nigg et al. 1999a, Chadwick et
al. 2006). However, due to relatively low reaction cross-sections (Figure 2) and typically
low contamination of the fast neutrons in the epithermal BNCT beams, fast neutron
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activation of the elements is small, and thus the uncertainty of the fast neutron fluence rate
measured is high (> 30%) (Serén et al. 1999).
Figure  2 Neutron activation reaction cross-sections utilized in BNCT neutron beam
characterization plotted from ENDF/B-VII.0 library data (Chadwick et al. 2006).
4.4 Secondary dosimetry: dual ionization chamber method
The dual IC method described in ICRU Report 45 (ICRU 1989) for fast neutron beam
dosimetry is the recommended method for direct measurements of the total neutron and
photon dose in BNCT (Rogus et al. 1994, Raaijmakers and Konijnenberg 1995, Kosunen
et al. 1999, Kortesniemi 2002, IAEA 2001, Riley et al. 2003). The total dose is measured
with the tissue-equivalent TE(TE) chamber and the photon dose with the nominally
neutron-insensitive Mg(Ar) or the C(CO2) chamber (Binns et al. 2005). The neutron dose
is estimated by subtracting the measured photon dose from the measured total dose, which
causes high uncertainty in the neutron dose measurement with the TE(TE) chamber
(Kosunen et al. 1999). Uncertainties of the IC measurements in the BNCT beams are 4–
20% for the photon dose and 5–30% for the fast neutron dose (Binns et al. 2005). Due to
low  fast  neutron  contamination  of  the  BNCT  beams,  the  high  uncertainty  of  the  fast
neutron dose determination is accepted. The percentage contribution of the individual dose
components to the weighted total brain dose at various depths calculated in the cylindrical
water phantom is shown in Figure 3. Improvement of the photon dose detection accuracy
is essential, since at certain depths in tissue (depending on the boron concentration), >
50% of the total weighted healthy tissue dose is due to the photon dose component.
Moreover, photon dose covers over 80% of the total physical absorbed dose in water.
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Figure 3 Percentage contribution of the individual dose components to the weighted total brain
dose at various depths in the cylindrical water phantom, when irradiated with a 14 cm diameter
circular FiR 1 beam. The brain is assumed to contain 19 ppm of 10B, 1.84 mass-% of nitrogen, and
10.6 mass-% of hydrogen. The weighting factors are: 3.2 for DN and Dfast,  1  for  Dg

and 1.3 for
DB.
The relative photon sensitivity for the Mg(Ar) detector was previously defined through
calibrations in water in a 60Co gamma source and in a 6 MV linear accelerator photon
beam (Kosunen et al. 1999).  However,  at  the  FiR  1  beam,  the  photons  in  the  water
phantom are mainly (90–98%) created within the medium, and they may have very
different energies and angle distributions than the photons from a high-energy accelerator.
Moreover, the existence of the chamber structures in the phantom changes the neutron and
photon field in water compared with situations without the presence of the chamber
(Kosunen 1999, Kosunen et al. 1999). Thus, determination of the IC sensitivity through
measurements in a high-energy accelerator photon beam may be inaccurate and should be
determined with computer simulations of the actual irradiation situation, mentioned
already in the Introduction, as suggested by Munck af Rosenschöld et al. (2002) and
Kosunen et al. (1999).
4.5 Dose planning
The absorbed dose in BNCT is due to nuclear interactions and thus the computational
approximations in use for photon and electron therapy cannot be adopted for BNCT dose
planning. Thus, specialized TPSs have been developed for BNCT use. To calculate the
neutron interactions within the body, the elemental composition of the organs needs to be
modeled, since the electron density information of the medical images cannot be utilized
for dose calculation.
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Regardless  of  the  interest  in  developing  a  TPS  based  on  faster  deterministic  calculation
methods (Kotiluoto and Hiismäki 2001), only MC-based software programs have been
applied in clinical BNCT. Four TPSs have been developed for BNCT purposes:
NCT_Plan (Zamenhof et al. 1996), Simulation Environment for Radiation Applications
(SERA) (Nigg et al. 1999b), Japan Atomic Energy Agency (JAEA) computational
dosimetry system (JCDS) (Kumada et al. 2004) and THORplan (Lin and Liu 2006, Li et
al. 2009). The precursors of the NCT_Plan and SERA were MacNCTPlan and
BNCT_Rtpe with minor differences from the recent versions.
Three  of  the  TPSs  (NCT_Plan,  JCDS  and  the  THORplan)  utilize  the  MCNP  code  for
particle transport calculations and use a voxel reconstruction technique to produce a
geometric description of the patient. In the voxel reconstruction technique, the medical
image data are partitioned into uniform cubes and each cube is assigned appropriate
material properties. Basically, each of these systems has unique procedures to convert
patient medical data into a voxel model and assign the elemental composition within the
model. Each system produces the input file for the MCNP calculations, and processes the
output file data, such as dose volume histograms and the isodose contour plots over the
medical images. The SERA system differs from these MCNP-based systems in its way of
creating the patient model and performing the MC transport. The SERA system is
described in detail in Section 5.1 and the JCDS system in Section 5.3.
The performance of the MacNCTPlan (Zamenhof et al. 1996) and BNCT_Rtpe (Nigg et
al. 1997) have been compared in a phantom study by Goorley et al. (2002), mainly
focusing on the voxel size in the patient model. Wojnecki and Green (2002) performed a
dose calculation comparison between the MacNCTPlan and SERA systems (Nigg, 2003)
in the phantom geometries. More recently, Casal et al. (2004) compared the calculations
performed with the NCTPlan (González et al. 2005) and SERA systems to the
measurements in a phantom at the RA-6 reactor facility in Argentina. The dose
calculations with the THORPlan have been compared with the NCTplan, SERA, and
MCNP in the modified Snyder head phantom (Li et al. 2009).
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5 Summary of the applied Monte Carlo codes
5.1 SERA treatment planning system
The SERA system consists of several software modules, including an image formatter and
editor, 3-D viewer, dose-contouring and -plotting tools, particle transport-modeling
interface, and a dose postprocessing function (Wessol et al. 2001). As mentioned in the
previous section, the SERA system differs from the other BNCT TPSs in its way of
producing the patient model and in tracking particles through this geometry. The patient
model is reconstructed using a pixel-by-pixel uniform-volume element (univel)
reconstruction method, and SERA’s own MC algorithm, seraMC, is applied for neutron
and photon transport calculations (Nigg 2003).
Any medical image modality can be used to create the patient model, since the model is
independent of the initial image data. Anatomical regions are delineated on the 2-D
medical images, and the delineated image slices are combined to form a 3-D patient
model.  The  regions  are  assigned  manually  with  the  tissue  data,  typically  obtained  from
ICRU Report 46 (ICRU 1992). The most significant difference between univel and
standard voxel-based reconstruction and tracking methods (as used in MCNP) is that
univel geometry enables use of the fast scan-line rasterization method, which allows rapid
particle tracking through the univel geometry (Nigg 2003). Univel volumes along the
particle track are investigated, and precise intersection points (‘distance to boundary’) are
rapidly calculated as the particle moves from one anatomical region to the next. The
photon and neutron transport are simulated using local material compositions set for each
anatomical region within the patient model.
Another  difference  from  the  other  BNCT  TPSs  is  that  radiation  transport  in  seraMC  is
based on multi-energy group neutron and photon cross-sections instead of pointwise cross-
sections (as in MCNP). The cross-section data in seraMC is based on the Evaluated
Nuclear Data File (ENDF) library versions ENDF-B/IV and ENDF-B/V. The seraMC
algorithm computes dose and fluence rates in the patient as a volume integral for each
anatomical region (Wheeler 1999). A virtual edit mesh of cubic voxel cells (default size 1
cm3) is imposed over all anatomical regions. The fluence and dose contribution, due to
every particle path, that intersects with the voxel cell, are tallied in the cell. After the MC
simulation, the pointwise dose is determined as a function of the volume-integrated values
in each voxel cell. Point dose is determined as a function of the nearest seven edit voxels
in orthogonal directions, except near the boundaries, where the nearest two voxels are
used (Wheeler 1999). Fluence shape in the orthogonal directions is assumed to be a
second-order polynomial. For dose calculation, flux-to-kinetic energy released in matter
(KERMA) conversion factors from MACLIB (ENDF-B/IV) library are adopted. The
interpolated surface dose may deviate from the real physical dose at the surface boundary,
becauset the steep dose gradient is not taken into account in the interpolation and fitting
schemes (Nigg 2003).
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In Finland, the SERA system is applied to the dose planning calculations in clinical BNCT
trials. The FiR 1 beam model is created with a 2-D discrete ordinate code transport code
(DORT) (Rhoades and Childs 1988, Seppälä 2002) and transferred to the SERA system.
In the DORT simulations, a coupled 67-group cross-section library Broad User Group
Library ENDF/B-80 (BUGLE-80) was applied, which includes 47 neutron energy groups
and 20 gamma energy groups specially defined for the light water reactor shielding
calculations based on the ENDF-B/IV library (Roussin 1980). The new versions of the
library (BUGLE-93 or BUGLE-96) have not been applied, albeit recommended by the
BUGLE developers, since the new libraries are based on updated ENDF-B/VI data (White
et al. 1996). The neutron beam model is validated with the neutron spectrum
measurement, using several activation foils (Serén et al. 1999). Due to small differences
between the measured and calculated neutron spectra and high levels uncertainty in the
measurements at certain energies, the clinical beam model was not normalized according
to the spectrum measured. The photon beam model has not been verified against
measurements, since the contribution of the primary photons to the total biological dose is
small in the phantom (or in the patient) (Seppälä 2002).
The SERA calculations have been validated for brain tumor dose planning (Seppälä 2002).
The beam model is normalized with the Au-RR measurements at the reference
measurement depth, 2 cm deep in the phantom. As mentioned in Section 4.3, the Au-RR
and Mn-RR measurements are used as the primary dosimetric methods for calculation
verification. At FiR 1, the original 55Mn(n,)56Mn and 197Au(n, )198Au reaction cross-
sections (based on the International Reactor Dosimetry File-90 (IRDF-90) library)
included in the SERA package are weighted with a Watt spectrum for fast neutrons, a 1/E
spectrum for epithermal neurons, and a Maxwellian spectrum for thermal neutrons
(Seppälä 2002). SERA calculations with the default-sized (1 cm3)  voxel  cells  have  been
found reliable in the homogenous medium inside the phantom, while 10–30%
overestimation of the dose and the RRs has been observed on the phantom surface and
near the air boundaries (Seppälä 2002, Seppälä et al.  2002). The effect of the reduced
voxel cell size in the calculations on the surface is worth evaluating.
Due to the typically low number of fast neutrons in the BNCT beams, a biased fast
neutron run function is included in SERA for better convergence of fast neutron
calculations.  If  the  biased  fast  neutron  run  is  specified,  a  contribution  to  the Dfast from
incident neutron energies greater than the given energy is added after a standard neutron
transport run (Nigg 2003). In the FiR 1 neutron beam, the fast neutron flux is only bout
1/30 of the total neutron flux, and thus considerably higher calculation time is required to
gain low statistical uncertainty at fast neutron energies. Thus, to obtain a practical dose
calculation time in the clinical dose planning, the biased Dfast calculation option has been
applied at FiR 1 (Seppälä 2002). However, notable differences between the Dfast values
calculated  with  the  SERA  biased  run  option  and  MCNP  were  later  reported  (SERA
underestimates Dfast by > 40%) (Casal et al. 2004, Albritton and Kiger 2006). A large
difference (3.67 times) between the calculated and measured  Dfast was reported by Riley
et al. (2008), when SERA calculations were compared with measurements performed by
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the MIT team at the FiR 1 beam. Consequently, Dfast determination with the SERA code in
the FiR 1 beam requires verification.
5.2 MCNP Monte Carlo code
One of the codes recommended for the BNCT dosimetric calculations (Voorbraak and
Järvinen 2003) is the General Monte Carlo N-Particle Transport Code (MCNP)
(Briesmeister  2000,  X-5  Monte  Carlo  Team  2008).  The  MCNP  code  was  used  as  a
simulation tool or as reference dose calculation method in Publications I–III. In
Publication VI, electron transport accuracy of the MCNP was determined.
The MCNP system is maintained by a large group at the Los Alamos National Laboratory
(Los Alamos, NM, USA) and was originally developed for coupled neutron-photon
transport for the nuclear reactor calculations. Later on electron transport capabilities were
included  in  the  code  and,  furthermore,  one  earlier  version  of  the  code,  Monte  Carlo  N-
Particle Code Extended (MCNPX) (Waters 2002, Pelowitz et al. 2011), can also handle
various other particles. The next version of the code, MCNP6 (Goorley et al. 2011),
combines the capabilities of the MCNPX and MCNP version 5, but in addition contains
new features not previously found in either code. The second beta version of MCNP6 was
released in early 2012 (Goorley et al. 2011).
The MCNP code is widely used, due to its reliability and great flexibility in coupled
photon-neutron transport calculations. The neutron energies in the code are from 10-11
MeV up to 20 MeV for all isotopes and up to 150 MeV for some isotopes, while the
energy regime for photons is from 1 keV to 100 GeV and for electrons from 1 keV to 1
GeV. The point-wise continuous-energy cross-sections are applied for photons and
neutrons based on more recent ENDF (ENDF-B/VI or ENDF-B/VII) data. All the
reactions given for neutrons in the cross-section library are simulated. Neutron absorption
is treated either in an analogue or implicit (the default) manner. The thermal neutron
scattering in the default mode is treated as a free-gas model, which includes thermal
motion of the nucleus, but neglects the complex chemical binding effects and interaction
of the target atom with the nearby atoms in the scattering kinematics (Briesmeister 2000).
For certain molecules and mixtures, the S() thermal-scattering treatment is available in
the code, which includes the complete thermal neutron-scattering law to account for the
molecular-binding effects of hydrogen in the materials. Accounting for the molecular-
binding effects of hydrogen in the biological materials is essential in BNCT dose
calculation (Goorley et al. 2002), and thus the S() treatment is applied for liquid water
and solid plastics in all the MCNP simulations of this thesis. For photons, the MCNP code
accounts for incoherent and coherent scattering, the possibility of fluorescent emission
after photoelectric absorption, and absorption in electron-positron pair production
(Breismeister 2000).
In terms of electron transport, MCNP is a class I CH code, and thus an electron’s energy
loss and direction are sampled from predetermined multiple-scattering distributions in case
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of every electron collision. Radiative energy loss is simulated explicitly in an analogue
manner. Electron (and positron) transport processes in MCNP5 account for angular
deflection through multiple Coulomb scattering, collisional energy loss with optional
straggling, and the production of secondary particles including K x-rays, knock-on and
Auger electrons, bremsstrahlung, and annihilation gamma rays from positron annihilation
at rest (X-5 Monte Carlo Team 2008). The most important electron transport algorithms
are the Goudsmit-Saunderson (Goudsmit and Saunderson 1940) theory for angular
deflections, the Landau (Landau 1944) theory of energy loss fluctuations, and the Blunck-
Leisegang (Blunck and Leisegang 1950) enhancements of the Landau theory (correction
for electron binding effects).
The multiple-scattering theory implies that, the electron step length must be long enough
to encompass many collisions, but short enough that the mean energy loss within any one
step is small. Thus, in the MCNP (as in all the ETRAN codes (Seltzer 1991)), the major
electron energy step is broken into smaller substeps of equal lengths. The representation of
the electron's trajectory as the result of many small steps is more accurate, since the
angular deflections per (sub-) step are then smaller (X-5 Monte Carlo Team 2008). In the
MCNP, the number of substeps is dependent on the average atomic number of the
material. The user can increase, but not decrease, the number of substeps per energy step
(the electron substep (ESTEP) parameter in the code). The MCNP manual recommends
increasing the ESTEP parameter in case the expected number of substeps in a material
region is less than 10. In particular, a very small material region may not accommodate
enough substeps for an accurate simulation of the electron's trajectory.  Thus, it may be
useful to increase the ESTEP number in the IC response simulations for the gas cavity, as
has been done in the first two IC response studies with MCNP by Roca et al. (2002) and
Munck et al. (2002).
In the MCNP versions earlier than MCNP5 (X-5 Monte Carlo Team 2008) release 1.40,
all parameters needed for sampling electron energyloss straggling were predetermined for
standard energy boundaries and for the corresponding electron path lengths. The problem
with this method is that an electron may not complete its major step before it reaches a
geometric boundary and a systematic error in energy loss calculation occurs, since the
actual major step length is less than the step length originally used for determining the
collisional energy loss. Two optional methods for choosing energy boundaries were
available by altering the 18th entry of the debug information card (DBCN): the default
MCNP logic (DBCN 18 card = 0) and the ITS electron energy indexing developed
previously for the ITS codes (DBCN 18 card = 1). Both these algorithms cause systematic
errors  in  the  electron  transport  calculations,  due  to  the  geometrical  and  energy  grid
resolution dependency (Jeraj et al. 1999, Chibani and Li 2002, Reynaert et al. 2002,
Schaart et al. 2002). In MCNP5 version 1.4 (X-5 Monte Carlo team 2008), the electron
transport has been improved by introducing a new detailed approach for electron transport
(DBCN 18 card = 2): instead of calculating the electron energy straggling in the
predetermined energy grid, the Landau distribution for energy straggling is sampled for
each energy step, using the specific energy of the electron and the actual step length. Other
electron transport events at the substep level (angular deflections, production of electron-
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induced x-rays, and knock-on electrons) are still pre-computed in both logics. The new
detailed electron transport model eliminates the step-size artifacts in a small geometric
volume in water (Hughes 2005).  Thus, in the recently released beta 2 version of MCNP6,
the new detailed logic for Landau electron energy straggling is set as the default option for
electron transport (Hughes 2011).
5.3 JCDS treatment planning system
The JCDS system creates a detailed 3-D model of a patient, based on CT and MR image
data for MC transport. Structures such as bone, soft tissue, and air are delineated, based on
the Hounsfield unit (HU) values in the CT images (Kumada et al. 2004). MR images are
used to delineate regions of interest within the structures. The JCDS system converts the
patient model into a voxel model (Kumada et al. 2009). Each voxel cell is assigned to the
proper material. The elemental data of each anatomical structure are defined according to
ICRU report 46 (1992), but can also be modified manually. The particle fluences and the
absorbed doses are calculated in the mesh elements superimposed over the patient model,
using the Mesh Tally function of the MCNP5 code (X-5 Monte Carlo Team 2008,
Kumada et al. 2006).  Mesh  Tally  calculation  requires  shorter  execution  time,  and  thus
higher resolution can be used in the patient voxel model, which enables accurate particle
transport near tissue boundaries (Kumada et al. 2006). After the particle transport
simulation, the JCDS system estimates the detailed dose distribution in the patient model
by interpolating the mesh tally calculation results. JCDS also provides information on the
patient’s positional data, which can be utilized by the patient setting system (Kumada et
al. 2004). The JCDS system is used as a comparative dose calculation method in
Publication III.
In the next version of the code, JCDS-FX, the MCNP code as a calculation tool is replaced
by the Japanese Particle and Heavy-Ion Transport code System (PHITS) (Iwasa et al.
2002), because the PHITS code can accurately simulate electrons, protons, and heavy
particles in addition to photons and neutrons (Kumada et al. 2009, Kumada et al. 2011).
The  JCDS-FX system is  also  able  to  handle  PET image  data  in  addition  to  MR and CT
data and it can handle a pixel-based voxel model of the patient, which further improves
estimation of dose. Since such a small voxel geometry slows down the MC simulation
considerably,  the  latest  version  of  the  JCDS-FX  system  includes  a  new  geometry
modeling function Multistep Lattice-Voxel (MLV) method, which enables creation of a
voxel model of different voxel sizes (Kumada et al. 2011). In the MLV method, uniform
material regions are described as single large voxels and regions consisting of two or more
materials are described as pixel-sized voxel cells, each labeled with an appropriate
material (Kumada et al. 2011). This modeling technique improves calculation time, since
the total number of voxels in the patient model is decreased.
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5.4 PENELOPE Monte Carlo code
PENELOPE is a code system for MC simulation of coupled electron-photon transport,
initially developed to simulate the PENetration and Energy LOss of Positrons and
Electrons in matter. PENELOPE was also used as a reference calculation method in
Publication VI.
The PENELOPE code performs particle transport in an arbitrary 3-D configuration of
materials for electron, positron and photon energy ranges from 50 eV to 1 GeV. Photon
interactions  are  simulated  analogously  event  by  event,  in  chronological  order.  For
generation of the electron and positron tracks, a class II CH method is implemented: all
interactions that involve changes in the kinetic energy or direction of flight are simulated
in an analogous manner above certain threshold values given for scattering angle and
energy loss. Below the threshold values, class I multiple-scattering methods are applied.
The particle-tracking algorithm of PENELOPE operates independently of interface
proximity  and  requires  only  knowledge  of  the  material  at  the  current  position  of  the
particle. Thus, the boundary-crossing artifacts are avoided. PENMAIN is a generic main
program of PENELOPE, that performs simulations of electron-photon transport in
complex material structures. It is well benchmarked against experimental data (Baro et al.
1995, Sempau et al. 1997, Sempau et al. 2003). Geometries and materials are modeled
using the subroutine PENGEOM, which is able to handle complicated geometries very
efficiently. The photoatomic database and the Compton momentum profiles are taken
from the Evaluated Photon Data Library 97 (EPDL97) (Cullen et al. 1997) and Biggs et
al. (1975) respectively. Atomic cross-sections for incoherent scattering of photons,
inelastic scattering of electrons and positrons, and positron annihilation are evaluated
directly from the analytical differential cross-sections (Salvat et al. 2003, 2008).
5.5 EGSnrc  Monte Carlo code
The  EGS  is  a  code  system  for  the  MC  simulation  of  electron,  positron,  and  photon
transport (Nelson et al. 1985) in any element, compound or mixture. EGSnrc is an
extended and improved version of the previous EGS4 system (Kawrakow and Rogers
2000) and has been used as a reference calculation method in Publication VI.
The EGSnrc system includes the user codes DOSRZnrc, FLURZnrc, CAVRZnrc, and
SPRRZnrc, for scoring the dose in a generalized cylindrical geometry, particle fluence in
the same geometry, a variety of quantities of specific interest to IC dosimetry calculations,
and for calculation of Spencer-Attix spectrum-averaged stopping power ratios for any
medium, respectively (Rogers et al.2011). The range of photon energies is between 1 keV
and several hundred GeV and that of charged particles from a few tens of keV up to a few
hundred GeV. The EGSnrc code employs the class II condensed method approach to
simulate radiative and collisional energy loss (without the energyloss straggling) of
electrons. The multiple scattering is simulated for steps of any size and moves from a
single  scattering  model  for  short  steps  to  an  accurate  multiple-scattering  model  at  large
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steps (Kawrakow et al. 2011). The user can choose between scattering based on
Rutherford scattering or scattering accounting for relativistic and spin effects. As
mentioned in Section 3.2.3, an accurate PRESTA-II algorithm is used for moving the
electrons and positrons from one position to another. To avoid boundary-crossing artifacts,
the electron/positron transport switches from CH to exact analogue modeling near
boundaries. The distance from the boundary where the exact model is turned on can be set
by a number of elastic-scattering mean free paths (the default value is 3). Bremsstrahlung
production is modelled using either Bethe-Heitler cross-sections or the National Institute
of Standards and Technology (NIST) cross-sections (Kawrakow et al. 2011). Compton
scattering is simulated, using either the Klein-Nishina or bound Compton model. It is
possible to use user-supplied atomic and molecular form factors for Rayleigh scattering.
The total photon cross-sections can be chosen from EPDL97, XCOM, or any other user-
supplied tabulation in addition to the default Storm and Israel tabulations.
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6 Methods for BNCT dosimetry
A major difference between dosimetry of BNCT and conventional radiotherapy beams is
that the epithermal neutron beams have unique spectral and angular distributions, (Rogus
et al.1994, Riley et al.2003, Raaijmakers et al.1997, Woollard et al.2001) and thus the
phantom geometries applied in the photon and electron beam dosimetry cannot be directly
applied in BNCT. The phantom dimensions, which provide full back-scattering conditions
at the reference measurement depth (reference phantom) and at every measurement point
(full-scanning phantom) need to be determined.
As mentioned earlier, the accuracy of the IC measurements and at the same time,
determination accuracy of the Dg and Dfast, is unsatisfactory. One reason for the inaccuracy
may be inaccurately determined response for mixed neutron-photon beams, which should
be determined through computer simulation of the measurement situation. However, the
simulation  codes,  EGSnrc  and  PENELOPE,  which  are  able  to  simulate  IC  response
accurately, are not able to simulate neutron interactions. For IC response simulations in
neutron beams, use of the MCNP code has been proposed (Munck af Rosenschöld et
al.2002). The applicability of MCNP code (version 5) for IC response simulations has
been investigated in comparison to EGSnrc and PENELOPE codes in Publication VI.
6.1 Reference phantom and water scanning phantom for BNCT
The MCNP code (version 4b) was used for determining the minimum dimensions for the
reference phantom and a large water-scanning phantom (Publication I). To determine the
impact of phantom size on the beam parameters at the measurement points, the water
phantoms  with  several  wall  lengths  were  simulated  and  the  results  were  compared  with
those obtained in a virtually infinite phantom, wherein the full-scattering conditions are
gained. The induced Dg, Dfast (E > 0.5 eV), total dose rates to ICRU brain (ICRU, 1992),
and the thermal neutron (E < 0.5 eV) and total neutron fluence rates were evaluated. The
beam gamma component was not considered, because at its maximum (at the beam
entrance), the beam gamma (primary photons) contribution to the total physical dose in the
water phantom is only 2% (< 0.2 Gy/h) in the FiR 1 beam.
The calculated Dg components  with  depth  in  the  phantom for  the  14  cm diameter  FiR 1
beam are plotted in Figure 4. It can be seen that the primary Dg in the phantom decreases
gradually with depth, while the secondary (or induced) Dg decreases with deep gradients
beyond the dose maximum, and thus at depths  6 cm, the contribution of primary photons
to the total photon dose is Dg 3–10%.
It was found that the minimum dimension for the reference phantom is a 40 cm wall
length  for  beam  diameters  from  14  cm  to  20  cm  in  the  FiR  1  beam.  In  the  smaller
phantoms, the uncertainty of the Dg increases, due to leakage from the geometry. For
undisturbed measurements of the thermal neutron fluence at the reference depth, the
margin between the beam aperture edge and phantom wall needs to be at least 3 cm and
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for the  Dfast at least 6–10 cm, regardless of the beam size. Correspondingly, undisturbed
Dg measurements  need  a  margin  of  approximately  10  cm.  Thus,  the  size  of  a  reference
phantom needs to be defined based on the Dg measurement requirements. A lower limit
for the phantom depth was not determined, but the 20 cm deep phantom was large enough
to provide undisturbed doses and fluences at the reference point.
Figure 4 Photon depth dose calculated with MCNP5 in the large water phantom (wall length 53.6
cm and height 49 cm) for the secondary and primary photons with the 14 cm diameter circular
beam aperture. The statistical uncertainty is  0.6% (1.
Only the largest phantom (56 cm × 56 cm and 28 cm deep) studied was large enough to
fulfill requirements for a large scanning phantom. The most distant measurement point
was found at a radial distance of 19.5 cm in the 14 cm beam, which sets s radial limit for
the phantom size. The large scanning phantom in BNCT needs to extented at least 7 cm
deeper than the most distant measurement point, which was found at 18 cm and 21 cm
depths for the 14 cm and 20 cm beam sizes, respectively.
In the other studies of this thesis, the dose distributions were evaluated in the cylindrical
water phantom (diameter 20 cm and length 20 cm) or in the similarly sized head geometry
(an anthropomorphic phantom, ellipsoidal Snyder phantom, and a patient’s head). At the
FiR 1 facility, the main dosimetric phantoms are the large water-scanning phantom (wall
length 51 cm and height 47 cm) with cylindrical extension (diameter 20 cm and length 20
cm) and the cylindrical PMMA phantom (diameter 20 cm and length 24 cm). To show the
impact of these real phantom geometries on the neutron and photon dose components, the
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radial dose profiles calculated with MCNP5 at a 2 cm depth in the water phantoms is
plotted in Figure 5 for the 14 cm diameter FiR 1 beam. It is clear from Figure 5 that
phantom geometry has no effect on the neutron dose components at radial distances within
4 cm from the beam axis. However, the Dg is 6–30% higher in the large phantom at every
point. In the cylindrical phantom, photons leak out more from the phantom, whereas in the
large phantom higher photon backscattering is obtained.
Figure 5 Radial distributions of the physical neutron and photon dose components calculated with
MCNP5 at the 2 cm depth in the cylindrical (symbol) and large (line) water phantoms for the 14
cm diameter FiR 1 beam. The statistical uncertainty (1 of the calculations is  0.6%.
6.2 Suitability of the MCNP5 code for IC response simulations
In Publication VI,  the purpose of the study was to evaluate the accuracy of the MCNP5
code in the electron transport calculations and suitability of the code for the IC response
simulations, using either the ITS-based electron transport model (MCNP5ITS) or the new
detailed algorithm for electron energyloss straggling (MCNP5new).  The  calculations  with
the EGSnrc and PENELOPE codes were used as a benchmark, due to their ability to
provide results that agree closely with the experimental data for photon and electron
beams (Doucet et al. 2003, Vilches et al. 2009, Rodríguez 2008, Sterpin et al. 2008) and
their capability for simulating the IC response with high accuracy (Kawrakow et al. 2000,
Sempau and Andreo 2006).
The accuracy of the MCNP electron transport was evaluated by comparing the depth dose
curves in water, using discrete energies (0.05 MeV, 0.1 MeV, 1 MeV and 10 MeV) for the
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broad (radius 10 cm) parallel electron beams in a water phantom subdivided into multiple
thin (1/30 of electron’s continuous slowing down approximation (CSDA) range, R0)
layers. For the IC response simulation evaluation, the absorbed dose was calculated in a
small gas cavity, comparable to an IC gas cavity placed at the reference measurement
depth in the water phantom and exposed to three different monodirectional high-energy
photon  beams:  a 60Co source, 6 MV linear medical accelerator, and a 2 MeV photon
source. The 2 MeV monoenergetic photon beam was studied, because it approximates the
hydrogen neutron capture gamma energy (2.2 MeV) which predominates in the water or
TE phantom in BNCT, as can be seen in the photon spectrum plot in Figure 6.
Figure 6 MCNP5 calculation for the photon spectra at the 2.5 cm depth, where the photon dose
maximum occurs in the cylindrical (diameter 20 cm) water phantom in the 14 cm diameter
circular beam at the FiR 1 facility.
The doses in three dosimetric gases were studied: air, argon, and methane-based TE-gas.
The gas cavity was modeled to be comparable to the cylindrical part of the ExradinTM M2
and T2 IC gas cavity (hollow cylinder of height 0.9 cm, outer radius 0.48 cm and inner
radius 0.23 cm, volume 0.50 cm3)  as  shown in  Figure  7.  In  the 60Co photon source, the
influence of the ESTEP parameter set for gaseous material on the MCNP dose calculation
was determined. The other simulation parameters applied in three codes are described in
Publication VI.
At the 10 MeV beam energy, the MCNP5new results agreed with PENELOPE within 2%
and  with  EGSnrc  within  1%,  whereas  the  MCNP5ITS results agreed with the reference
codes within 2% only at depths up to 0.4R0 and showed strong boundary-crossing artifacts
at the deeper depths. At every lower beam energy, both the MCNP5 electron transport
models deviated from the reference calculations by > 2%. The deviation was greatest at
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the 0.1 MeV and 0.05 MeV energies and at the tails of the dose curves, especially in
MCNP5ITS.
Figure 7 Illustration of the simulation geometry (left) and a cross-sectional view of the ExradinTM
ionization chamber geometry (right). The gray area of the ionization chamber image corresponds
to the gas volume studied (dark gray) placed in the water cylinder in the simulation geometry.
Since the boundary-crossing artifacts were observed in the MCNP5 results, further
simulations were performed by calculating the depth doses in the single scoring cells and
comparing the results with those obtained for multiple layers. When the excessive
boundary crossing was discarded, the dose calculation improved dramatically at the dose
curve tails, but still the deviation from the reference codes was large (up to 20%) for the
0.1 MeV and 0.05 MeV electron beams. As was expected, the boundary-crossing artifacts
were more notable in the MCNP5ITS than  in  the  MCNP5new, because the energy loss
sampling in MCNP5new is independent of interfaces. The boundary-crossing artifacts with
the MCNP5new were found only for the 0.1 MeV and 0.05 MeV beams.
For  the  IC  response  simulations,  it  was  found  that  the  MCNP5ITS dose estimate agreed
with both the reference codes in every gas, except in argon at 2 MeV beam energy, in
which case the dose was overestimated by 1.4% (± 1%). The MCNP5ITS dose calculations
were nearly independent (maximum change 2%) of the ESTEP value chosen, whereas the
MCNP5new dose  estimate  was  highly  dependent  on  the  gaseous  material  and  the  ESTEP
value selected for the gas. The MCNP5new agreed with the reference codes only if the
default ESTEP value was applied for argon and if the ESTEP value was increased to 500
for TE-gas and air. When the ESTEP value was increased, the MCNP5new dose estimate
decreased and, thus disagreed with the reference codes by 15% at most. The reason for the
dose reduction at high ESTEP number was that the electron fluence was reduced at the
smallest energies along with increase in the ESTEP number (as shown in Figure 8 for
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argon), most probably because implementation of the Goudsmit–Saunderson multiple-
scattering theory in MCNP5 is not valid for very short substep lengths.
Figure 8 Electron energy spectra in the argon-filled gas cavity in the water phantom exposed to
the 60Co beam calculated with MCNP5new, using various ESTEP values (number of substeps per
electron energy step) for argon. The error-bar of the electron fluence is 1–3% (l) per energy bin.
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7 Dose planning calculations
A combination of simple phantoms and more realistic conditions is recommended for the
quality assurance and analysis of a BNCT TPS (IAEA 2001, Albritton and Kiger 2006).
The basic features of the TPS, such as the effects of different cross-section libraries and
fluence-to-dose conversion factors can be analyzed in simple phantoms with simple
neutron sources. A more complex phantom with several materials and boundaries, and
possibly irregular surface structures, is required for more realistic performance analysis.
For the final assurance of the TPS, the dose calculation evaluation needs to be performed
with a realistic neutron source in clinical patient cases.
The dose calculation performance of the SERA system was evaluated in comparison to
measurements (Publication IV) and reference calculations, using either the MCNP code
(Publications II and IV) or the JCDS system (Publication III). In Publication II, the dose
calculation was evaluated in simple mono-energetic and -directional neutron sources in two
ellipsoidal Snyder (Snyder et al. 1969) head phantoms. The aim was to evaluate the effect
of the cross-section libraries and the dose calculation methodologies. In the publication III,
the SERA dose calculations were compared with the JCDS system in a brain tumor patient
case applying the clinical FiR 1 neutron beam. The aim was to determine the influence of
the actual patient geometry in the dose calculations and verify the volumetric dose
calculations in each region of interest. In the Publication IV, the SERA calculations were
evaluated in a simple cylindrical water phantom and in a more complex irregular
anthropomorphically shaped water head phantom by comparisons to measurements and
MCNP calculations in the FiR 1 beam.
7.1 Calculation comparison with mono-energetic neutron beams
In Publication II, the neutron fluence and dose distributions in two ellipsoidal phantoms
were investigated for six mono-directional and -energetic neutron beams of energies (25
meV,  1,  5,  10,  100  keV  and  1  MeV),  which  were  also  applied  in  the  BNCT  simulation
studies by Goorley et al. (2002) and Wojnecki and Green (2002). MCNP code version 4C2
was applied for the reference calculations with cross-sections from the ENDF-B/VI data
library. In SERA, the cross-sections data from ENDF-B/IV and ENDF-B/V libraries are
reprocessed into 94 neutron energy groups, as mentioned already in Section 5.1. The
neutron cross-sections in SERA are listed as the total elastic scattering and the total
absorption cross-sections instead of exact nuclear reaction cross-sections for the nuclides.
In the water phantom, thermal (E < 0.414 eV) and total neutron fluences, as well as Dfast,
Dg, and the total dose were compared. The more realistic head phantom was modeled,
including the skin, skull, and brain regions with material compositions according to ICRU
report 46 (ICRU 1992) (listed in Table 2). The biological doses were evaluated and the
following wi values applied: 1 for Dg, 3.2 for Dfast and DN, 1.3 for DB in brain, and 2.5 for
DB in skin.
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Table 2 Elemental compositions (percentage by mass) of body tissues applied for
the Snyder phantom, according to ICRU report 46 (ICRU 1992).
Tissue H C N  O Other
Brain 10.7 14.5 2.2 71.2 0.2 Na, 0.4 P, 0.2 S, 0.3 Cl, 0.3 K
Skin 10.0 20.4 4.2 64.5 0.2 Na, 0.1 P, 0.2 S, 0.3 Cl, 0.1 K
Cranium 5.0 21.2 4.0 43.5 0.1 Na, 0.2 Mg, 8.1 P, 0.3 S, 17.6 Ca
In the water phantom, high discrepancy (17–24%), between the SERA and MCNP neutron
fluences was obtained at the thermal (25 meV beam) and fast (1 MeV beam) neutron
energy, due to differences in the oxygen and hydrogen elastic-scattering cross-sections for
water at these energy ranges (plotted in Figure 9 and Publication II). At neutron beam
energies between 1 keV and 100 keV, the codes agreed generally well (within 5–6%) and
large differences in the cross-sections were not observed. At thermal neutron energy, the
total neutron cross-section is lower for SERA, due to constant elastic scattering cross-
sections, suggesting that the thermal neutrons are less likely to interact with the medium
and have longer mean free paths. Consequently, SERA tended to overestimate the neutron
fluence  in  comparison  to  MCNP at  neutron  beam energies  <  1  eV.  The  only  other  major
difference in the cross-sections for water was in the oxygen elastic-scattering in the energy
region >100 keV, where the cross-section peaks are flattened out in multi-group
interpretation. The flattened cross-section peaks resulted in higher neutron fluence, due to
lower collision probabilities and longer mean free paths, as observed for the 1 MeV neutron
beam.
Figure  9 Neutron elastic-scattering cross-section for 1H and absorption cross-sections for 16O
applied in the SERA and MCNP. The SERA cross-section data were provided by the code
developers and the ENDF-B/VI cross-section data is taken from Rose (1991).
When the absorbed doses were compared, the largest differences between the SERA and
MCNP results were observed for the Dg and Dfast values. SERA provided 4–22% higher Dg
than MCNP for every neutron beam studied, because the hydrogen neutron absorption
cross-section is higher in SERA at energies < 2.4 eV and thus photon production has higher
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probability of occuring. For fast neutron beams (> 10 keV), SERA provided a maximum of
21% higher (at 1 MeV) and 43% lower (at 100 keV) Dfast values  than  did  the  MCNP.
Deviation between the codes was due to flattened cross-section peaks in SERA at > 400
keV and due to different calculation methods at 100 keV. At beam energies of 1–10 keV,
the maximum difference in total weighted doses between SERA and MCNP was only 2–
3%, due to minor contribution of the Dg component to the total weighted dose. At the 25
meV  beam  energy,  SERA  overestimated  the  total  dose  by  up  to  17%  in  comparison  to
MCNP,  due  to  overestimation  of  the Dg component as explained above. For the fast
neutron beams, high differences for the total absorbed doses were obtained, due to the high
contribution of the Dfast and Dg.
In the more complex Snyder head phantom, the neutron reaction cross-sections for 14N, 12C
and 10B need to be compared, in addition to cross-sections for 1H and 16O, since they
contribute to neutron transport within the phantom. The neutron fluence and total weighted
dose comparison results in the Snyder head were similar to those calculated in the water
phantom. At beam energies of 1–100 keV, the maximum difference between the total
weighted doses by SERA and MCNP was somewhat higher (6%) than in the water
phantom. High differences at the 25 meV and 10 MeV beam energies were obtained for all
the individual dose components, mainly due to differences in the hydrogen and oxygen
cross-sections, as explained earlier, but also due to similar differences in the nitrogen and
carbon cross-sections (Figure 10 and Publication II).
Figure 10 Neutron elastic scattering cross-
section for 10B and absorption cross-sections
for 12C and 14N applied in the SERA and
MCNP. The SERA cross-section data is
provided by the code developers and ENDF-
B/VI cross-section data were taken from Rose
(1991).
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For beam energies at 1–100 keV, SERA overestimated the DB and DN by a maximum of 9–
12% and Dg by a maximum of 5–7%. Since at these energies, the neutron absorption cross-
sections for 10B and 14N are very similar in the codes, the calculation difference was partly
due to differences in neutron transport and partly to differences in the dose calculation
methods.
7.2 Dose calculation verification in a clinical beam
In the previous section, the neutron source specification was simply forward-directed and
defined exactly the same way in the two codes without any normalization. The SERA and
MCNP calculations are compared, applying a real neutron source, the FiR 1 epithermal
neutron  beam,  in  the  Publications  III  and  IV.  In  the  FiR 1  beam model,  the  energies  and
angular distributions for neutrons and photons are averaged for the surface source model
applied in SERA and MCNP. The source model is located inside the beam collimator, at
the surface 5 cm inward from the beam aperture. The only difference between the SERA
and MCNP source descriptions is that in MCNP, the photon and neutron sources are
modeled separately in independent simulation runs. As mentioned earlier, this clinical
source model is normalized by the ratio of measured and calculated Au-RR at the 2 cm
depth in the cylindrical PMMA phantom (diametric Ø 20 cm, length 24 cm), since the
patient’s head is similar to that size and the foil placement is accurate in the solid phantom.
In the dosimetric calculations at the FiR 1 beam, the MCNP source model is normalized
with  the  same  RR  ratio.  The  normalization  factors  (RR  ratios)  are  slightly  different  for
SERA and MCNP, 0.94 and 0.96, respectively, in cylindrical geometry.
In brain cancer BNCT, as well as in the study described in the previous section and in
previously published phantom studies for the FiR 1 beam (Seppälä 2002, Uusi-Simola
2009, Kortesniemi 2002), the phantom is usually placed as near as possible to the beam
aperture plane, the ASD being zero. For HN cancer patients, the ASD is increased to 5 cm,
due to lack of space in the patient treatment position. The normalization factors for SERA
and  MCNP  were  defined  for  increased  ASD  of  5  cm,  both  of  which  were  the  same  as
defined for the ASD of 0 cm (Publication IV).
In every study of this thesis, the neutron dose calculations with MCNP were performed
identically, applying the track length estimate tally F4 with the tally multiplier card
counting total heating in MeV per collision for the hydrogen, boron, and nitrogen neutron
reactions. The only difference was that, in Publications III and IV, only the 1H(n, n’)
proton-recoil was accounted for in Dfast, whereas in Publication II, neutron interactions with
oxygen in water and carbon in brain were also included. In the FiR 1 beam, the proportion
of the carbon and oxygen doses of the total Dfast in brain tissue is only 1–2% and 4–5%,
respectively (plotted in Figure 11). The Dg was calculated in the same way in the
Publications II and IV, applying the total energy deposit tally F6, whereas in the
Publication III, the Dg was calculated according to clinical JCDS dose planning, applying
the F4 tally with the 1977 American National Standards Institute/American Nuclear
Society (ANSI/ANS) (ANS-6.1.1 Working Group, 1977) flux-to-dose conversion factors
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for photons in the tally multiplier card. The RRs were calculated with MCNP, using the F4
tally with the tally multiplier card counting the total number of (n, ) reactions in gold and
manganese. In SERA, the RR cross-sections specially modified for the FiR 1 neutron
spectrum were applied, as mentioned already in Section 5.1, whereas in MCNP, the
standard pointwise ENDF-B cross-sections were used.
The SERA dose planning calculations were evaluated in the cylindrical water phantom and
in the water-filled anthropomorphic head phantom in comparison to the IC and activation
foil measurements, and the MCNP5 calculations in Publication IV. The major purpose was
to verify the SERA dose planning calculations with the increased ASD of 5 cm in these two
phantom geometries. In addition, the influence of reduced voxel size and biased fast
neutron simulation function in SERA were examined.
Figure 11 Dose components in brain tissue due to fast neutron interactions with 16O (DO-16), 12C
(DC-12) and 1H (DH-1) calculated with MCNP5 in the cylindrical water phantom with the 14 cm
diameter circular FiR 1 neutron beam.
In the Publication III, actual dose plans calculated with the SERA and JCDS systems were
compared. The main differences between the SERA and JCDS codes are in patient model
creation and the MC engines. The SERA system creates the univel model, which has a
resolution of one image pixel, whereas the JCDS creates a voxel model. Even if a voxel
size can be reduced to an image pixel size, the dose calculation time in the JCDS becomes
impractical if pixel-sized voxels are used, and thus the voxel size must be compromised
between calculation time and spatial accuracy. The JCDS uses the MCNP code as the MC
engine. Differences related to MC transport between the codes have already been analyzed
in two previous sections and in Publications II and IV. However, the dose calculation
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results provided by the JCDS are not pure MCNP results, but were interpolated by the code
for  points  of  interest.  Thus,  in  the  JCDS  and  SERA  dose  calculation  comparisons  in
patients, the same differences were included as in the MCNP and SERA comparisons
(different MC transports, cross-section library forms, and dose calculation parameters), but
the effects of the various patient geometry and dose output methods (individual
interpolations) were also shown.
7.2.1 Cylindrical water phantom
In the cylindrical water phantom, the SERA calculations were compared with the Mn-RR
and Au-RR measurements, and the Dg measurements with the Mg(Ar) chamber and the
MCNP calculations.
The SERA and MCNP calculations for the Au-RR were within ± 4% and ± 5% for ASDs
of 0 cm and 5 cm, respectively, while the Mn-RR agreed somewhat better within ± 3% and
± 4%, respectively, at depths of 0.5–10 cm in the phantom. Due to inaccuracies in the FiR 1
beam model (the thermal neutron fluence was underestimated and epithermal
overestimated), shown already by Serén et al. (1999), disagreement was found between the
MCNP and experiments on the phantom surface with ASD = 0.
The SERA and MCNP predictions for the Dg agreed within 2–3% at depths > 0.5 cm in the
phantom. High discrepancy (5–13%), which increased with depth in the phantom, was
observed between the measured and calculated Dg values at certain depths, despite a newly
defined calibration factor applied for the IC signal interpretation.
The neutron-induced dose components were not directly measured, but the SERA and
MCNP calculations were compared. With both ASDs studied, the DB and DN values agreed
within 3–4% at depths > 0.5 cm in the phantom. The difference between the codes was
nearly the same as that observed for the Au-RR and Mn-RR calculations, and thus the
difference was due to the neutron transport simulations, not to the varying dose calculation
methods.
To prove the adequacy of the Au-RR and Mn-RR measurements as verification methods
for dose planning calculations at FiR 1, the RR depth profiles were compared with
individual dose component profiles normalized to unity. Exactly the same distribution was
found for the Mn-RR, DB  and DN values with depth in the phantom (Publication IV, figure
7).
For the Dfast, large (34–60%) deviation was observed between SERA and MCNP5, as
expected, since the biased fast neutron run was applied in SERA. When the biased fast
neutron  run  was  discarded,  the  SERA Dfast agreed notably better (within 8%) with the
MCNP5 results on the phantom surface at depths up to 2.5 cm, but the dose calculations
showed poor statistical accuracy at deeper depths. Computing times for statistically
accurate Dfast calculations without biased fast neutron runs are clinically impractical (30
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fold compared with thermal neutron run). Although the calculations tended to
underestimate Dfast,  the  MCNP5  results  were  in  line  with  the  experimental  data,  with  an
uncertainty of 30% obtained by the MIT group at FiR 1 (Binns et al. 2005, Riley et al.
2008).
The doses obtained with SERA, using two dose-plotting commands, the point-edit and
isodose contours, were compared. The results agreed within 3–5% in the phantom for every
dose component. As shown in Figure 12, the point-edit tends to overestimate the dose
compared  with  the  isodose.  Both  SERA  results  agreed  equally  well  with  the  MCNP5
calculations.  All  the  rest  of  the  SERA  dose  results  in  this  thesis  were  obtained  with  the
point-edit command, as in the previous dosimetric studies, despite the point-edit function in
SERA shows erratic behavior in interpolating the results at the voxel boundaries. In clinical
dose planning at FiR 1, the point-edit command is rarely used. Instead, the isodose contours
and dose volume histograms are applied. The dose volume command of SERA was verified
against the JCDS code in the Publication III.
7.2.2 An anthropomorphic RSVPTM phantom
To investigate the influence of more complex geometries on dose planning calculations, the
SERA calculations were compared with the Mn-RR and Au-RR measurements in an
anthropomorphic Radiosurgery Verification Phantom (RSVPTM, The Phantom Laboratory,
Salem, NY, USA). For the simulations, the same procedures were applied as in the patient
treatments:  the  phantom model  was  created  based  on  CT images  of  the  phantom and the
two-field dose plan was calculated.
The SERA calculations with the default voxel size (1 cm3) for the Mn-RR agreed within
5% with the measurements at the points of relevance inside the phantom. When the SERA
calculations were repeated with the reduced voxel size (0.5 cm × 0.5 cm × 0.5 cm and 0.25
cm × 0.25 cm × 0.25 cm), the deviation from the measurements increased inside the
phantom, due to unphysical fluctuation of the calculation results (shown in Publication IV,
Figure 8). The fluctuation was not related to statistical uncertainty of the results, since the
number of simulation particles per each voxel was the same as in the 1 cm3 voxel (0.25 cm
voxel) or greater (in the 0.5 cm voxel). Instead, the fluctuation could have been caused by
the interpolation scheme included in the code, clearly indicating that reduced voxel sizes
should not be applied when doses inside the phantom or patient are analyzed.
However, when the activation measurements were considered on the phantom surface,
agreement between the SERA calculation and the measurements increased at nearly every
measurement point with the highest neutron fluence, when the voxel size was reduced from
1 cm to 0.5 cm or 0.25 cm.
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Figure 12 Difference between SERA dose calculation results obtained with point-edit (line) and
isodose contour (symbol) commands. The boron dose (DB) was calculated for 1 g/g (ppm) of 10B.
7.2.3 Brain cancer dose planning: SERA verification against JCDS
For the TPS comparison, a brain cancer patient dose plan was first performed with the
SERA system, following the Finnish dose planning protocol of BPA-mediated BNCT for
recurrent brain tumors (Joensuu et al. 2003, Kankaanranta et al. 2011). The univel patient
model created with SERA was converted into grayscale images to reconstruct exactly the
same  patient  model  with  the  JCDS.  Each  grayscale  was  labeled  as  a  single  body  region
with tissue composition from ICRU Report 46 (ICRU, 1992). The body regions are listed
in  Table  3.  Two  neutron  fields  (anterior  and  posterior  to  the  patient)  of  diameter  14  cm
were applied in the dose plan and weighted 65:35, respectively. The dose calculation
parameters applied are listed in Table 3 and the simulation parameters in Table 4. In SERA,
the biased Dfast calculation was applied according to the clinical protocol.
Table 3 Applied body tissues and 10B concentrations for the segmented regions in the patient
model and weighting factors in the dose calculation. The elemental compositions of the body
tissues are taken from ICRU report 46 (ICRU 1992). The planning target volume (PTV)
includes tumor, edema, and a 2 cm margin.
Region Body tissue 10B concentration Weighting factors for the dose
components
from ICRU (g/g) DB DN Dfast
Skin Skin 28.5 2.5 3.2 3.2
Brain Adult brain 19 1.3 2.68 3.16
Cranium Cranium - - - -
PTV Adult brain 66.5 3.8 2.68 3.16
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Table 4 Simulation parameters in the SERA and JCDS systems. The calibration factor is defined as
the ratio of measured to calculated 197Au(n,) reaction rate in the cylindrical PMMA phantom.
SERA JCDS
Patient model resolution 0.1 cm 0.2 cm
Dose calculation voxel size 1 cm × 1cm × 1 cm 0.5 cm × 0.5 cm × 0.5 cm
Calibration factor 0.94 0.96
Number of simulation histories 5 × 107 ~108
The epithermal neutron fluence rates calculated for the individual beams with SERA and
JCDS  agreed  within  ±  2%  at  the  patient  surface,  and  the  agreement  was  within  ±  5%  at
depths up to 7.0 cm. SERA overestimated the thermal neutron fluence rate in comparison
to JCDS by 14–36% on the patient surface and at depths up to 0.5 cm, while agreement
between the codes was mainly within 5% at depths of 2–7 cm. Unlike in the phantom study
(Publication IV), differences between the codes for DN and DB deviated systematically from
the thermal neutron fluence calculation difference. Somewhat better agreement between the
codes was found for the DB estimates than for DN and the thermal neutron fluences. SERA
overestimated the Dg by up to 9% in comparison to JCDS at all depths (at the surface even
more), due to the different flux-to-dose conversion factors applied in SERA and JCDS
dosimetry (plotted in Figure 13).
Figure 13 Photon flux-to-dose conversion factors from the ENDF-B/VI (Rose 1991) library applied
in SERA and from the 1977 ANSI/ANS library (ANS-6.1.1 Working Group 1977) used in JCDS.
At the phantom surface and depths < 0.5 cm, SERA underestimated the fast neutron
fluence by 4–13% in comparison to the JCDS. At deeper depths, the fast neutron fluence
rates agreed within 8–10% at depths up to 10 cm. However, deviation between the Dfast
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values was substantially larger (up to 35%), due to erroneous biased fast neutron run in
SERA. If the biased fast neutron run was omitted and initial simulation neutron number (of
all energies) is increased from 50 to 100 million, the Dfast calculation difference was
reduced to 1–6% at shallow depths (< 2 cm in tissue). At deeper depths, the statistical
accuracy of the SERA results was poor.
The  total  weighted  dose  rates  to  brain  and  tumor  obtained  with  SERA and JCDS for  the
anterior field are shown in Figure 14. At depths inside the skull, the total weighted brain
doses agreed within 10% at depths up to 15 cm (5% isodose) and tumor doses within 5% at
depths up to 7.3 cm (37% isodose) for both the fields. The total weighted brain doses
agreed within 3–4% at all depths.
The combined two-field dose plans are compared in Table 5. The differences between the
codes for the total maximum weighted doses were small, 3% for the normal brain dose and
4% for the PTV and tumor doses, while the corresponding average dose differences were
larger: 8%, 4% and 10%. Large (up to 32%) calculation differences were found for the
Dfast, which covers only < 1% of the total maximum tumor and PTV doses, but about 6% of
the total maximum brain dose. About 99% of the total tumor and PTV doses and over 90%
of the total brain dose were produced by the thermal neutron-induced dose components
(DB, DN, and Dg). The differences between the codes for the maximum DB, DN, and Dg
were, respectively, 1%, 3%, and 13% in brain and 4%, 2%, and 8% in tumor.
Figure 14 SERA (line) and JCDS (symbol) calculations for the total depth distributions in brain and tumor
for the anterior field, using a 14 cm diameter circular FiR 1 beam. The boron dose (DB) was calculated for
19 mg/g (ppm) of 10B in brain and 66.5 g/g (ppm) 10B in tumor.
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8 Applicability of the D-D and D-T fusion neutron sources
for BNCT
As already mentioned in Section 3.1.1, compact D-D and D-T fusion neutron sources have
been under development at LBNL for over a decade (Reijonen et al. 2004, 2005). The
applicability of some designs of the sources for brain cancer BNCT was examined by
Verbeke et al. (2000). For moderation of the fusion neutrons down to epithermal neutron
energy, materials similar to those used  for moderation of the reactor-based neutrons, such
as aluminum, aluminum fluorides, lithium and lithium fluorides, iron, magnesium fluoride,
metallic aluminum and bismuth and its fluorides, lead, and its fluorides have been
suggested (Verbeke et al. 2000, Cerullo et al.2004, Durisi et al.2007, Publication V). In
addition, use of fission converter to multiply the neutron yield has been investigated (Lou
et al. 2003).
For reasons mentioned in Section 3.3.2, the tumor BNCT treatments have been of interest.
The applicability of D-D and D-T fusion-based neutron generators for external liver BNCT
was evaluated by means of dose calculations with the SERA system (Publication V). The
neutron generator model studied was developed to allow neutron yield of 1012 neutrons per
second from D-D fusion and 1014 neutrons per second from D-T fusion. Iron and
FluentalTM were used as moderator materials. At first, an iron layer was used to decrease
the fast neutron energy down to energies below 1 MeV. For D-T neutrons, the advantage of
iron is that while the neutrons are slowed down, they are also multiplied, due to the (n,2n)
reaction, which occurs above 8 MeV. After the iron layer, a FluentalTM layer was used to
decrease the neutron energies further down to epithermal energy range. Finally, the neutron
beam was collimated with bismuth and a lithiated polyethylene collimator. Rectangular
beam apertures (20 cm × 20 cm and 25 cm × 25 cm) were applied and the optimum
collimator thickness was studied.
The patient model was created based on axial abdominal CT scans. Dose calculations were
performed for the single beams and three combined beams. The maximum BNCT dose to
healthy liver was limited to 12.5 Gy (W) and it was proposed that BNCT would be a
possible  treatment  for  liver  tumors,  if  a  >  30  Gy  tumor  dose  throughout  the  liver  were
achieved. The boron concentration of the healthy liver tissue and tumor were assumed to be
the same as those measured in an actual patient BNCT (Pinelli et al. 2002):  8 ± 1 ppm and
47 ± 2 ppm, respectively.
With a single irradiation beam, the deepest penetration was achieved with the 25 cm × 25
cm beam size and 15 cm thick collimator with D-D and D-T sources, which led to tumor
doses of 11 Gy (W) and 10 Gy (W), respectively, at the deepest depth in the liver (12 cm
from  the  skin).  The  irradiation  time  with  the  D-D  source  was  calculated  to  be
unrealistically long, over 3000 minutes, but with the D-T source clinically relevant, at 56
minutes.
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When the three beams were combined, using a D-D source, the largest liver volume (>
57%) was covered with a 30 Gy (W) isodose, using either a 20 cm or 25 cm diameter
beam. For a D-T source, a 25 cm diameter beam and 15 cm thick collimator were needed to
cover the equivalent liver volume. The maximum tumor dose was 68–71 Gy (W) in every
case and the minimum tumor dose was about 8 Gy (W) (11% isodose) at the most distant
point in the liver. The irradiation times required for the three-beam treatments were 3500–
7500 minutes for the D-D source and 63–128 minutes for the D-T source. Clearly, more
powerful D-D fusion neutron sources are required for clinical applications. The D-D
neuron yield should be at least 6 × 1013 neutrons per second and D-T neutron yield 10132
× 1013 neutrons per second for clinically adequate 1 hour treatment time, which requires,
respectively, 60 times and 12 times more powerful sources than those studied here.
8.1 Comparison of the fusion-based and FiR 1 neutron beams
To compare the fusion-based neutron sources with the FiR 1 beam, the depth dose
distributions according to the brain cancer BNCT protocol were calculated with
MCNP5 in a water phantom, using the fusion neutron beams described in previous
section and Publication V. The collimator size was reduced to 15 cm × 15 cm in
diameter to be better comparable with the clinical 14 cm diameter FiR 1 beam.
The depth dose distributions from the fusion-based neutron beams and the FiR 1 beam
for brain tissue and tumor are compared in Figure 15. The fusion neutron sources
caused  higher  surface  doses  due  to  a  harder  neutron  spectrum  than  that  of  the  FiR  1
beam.  Using  the  boron  concentration  (1.5  times  that  of  blood  or  brain)  and  the  CBE
factor  of  2.5  commonly  applied  for  skin,  the  skin  dose  was  about  11  Gy (W) for  the
fusion neutrons, which is a lower dose than that resulting in the acute skin toxicity TD
(15–20 Gy for 100 cm2 of skin) reported for BNCT (González et al. 2009). Due to the
more energetic neutron spectrum, the fusion neutron beams also penetrated deeper than
the FiR 1 beam. For the fusion neutrons, the maximum tumor dose was obtained at the
3 cm depth and the advantageous depth (the depth at which the tumor dose is as large
as the maximum brain dose) is at 10 cm, whereas the corresponding values for the FiR
1 beam are 2 cm and 9 cm, respectively. The fusion neutron sources clearly provided a
lower  tumor  (68–70  Gy  (W))  dose  maximum  than  the  FiR  1  beam  (76  Gy  (W)).  To
achieve an equivalent treatment time with the fusion neutron generators and the FiR 1
beam, the fusion neutron yield needs to be 3 × 1013 neutrons  per  second for  the  D-D
source and 4 × 1013 neutrons per second for the D-T source. The geometry studied has
been estimated to yield 1012 neutrons per second D-D fusion neutrons and 1014 neutrons
per second, at an accelerator voltage of 120 kV and 2H current of 330 mA . This
number for the D-T source is theoretically high enough for clinical BNCT, while a
clinical D-D fusion neutron source requires almost 30 times more beam power.
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Figure 15 Total weighted doses for brain (lower set of curves) and tumor (upper set of curves)
calculated with MCNP5 for FiR 1 (14 diameter circular) and for the D-D and D-T fusion
neutron beams (15 cm diameter rectangular) normalized to maximum dose to brain (12
Gy(W)). The weighting factors and boron concentrations (19 ppm for brain and 66.5 for tumor)
are according to the FiR 1 dosimetry for brain cancer treatments (Kankaanranta et al. 2011).
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9 Discussion
9.1 Dose planning
Various cross-section file forms applied in SERA and MCNP caused negligible calculation
deviation in the BNCT dose at the energy range of clinical epithermal neutron beams.
However, in neutron moderation, it should be noted that multienergy group forms applied
in SERA flatten out the cross-section resonance peaks at high energies (> 100 keV and > 1
MeV).
When  the  SERA  and  MCNP  calculations  were  compared  using  a  clinical  epithermal
neutron beam of the FiR 1 facility, the thermal neutron-induced DB and DN and the Dg
agreed within 4% at every depth in the water phantom, except on the phantom surface. The
erratic biased fast neutron run option in the SERA system leads to significant
underestimation (up to 30–60%) of Dfast, while the standard SERA neutron run provides
reliable Dfast calculations, but the simulation time must be increased by 30-fold to obtain
statistically accurate results.
Use of 55Mn(n, activation RR measurements as the primary dose planning verification
method is justified, since the RR distribution acts exactly like the DB and DN dose (which
cover most of the total weighted healthy tissue dose at FiR 1) distribution with depth in the
phantom. The reduced voxel cell size (< 1 cm) in the SERA edit mesh improves dose
calculation accuracy on the phantom surface and is recommended for in vivo dosimetry
calculations.
The differences in patient dose calculations between SERA and the JCDS system are very
similar to those observed in the phantom study between SERA and MCNP. The JCDS-style
dosimetry (the applied flux-to-dose conversion factors) underestimated Dg by 20–30% in
comparison to SERA. The difference between SERA and JCDS for the total weighted
tumor, PTV, and healthy brain doses are only 3–4%, regardless of the discrepancy in Dg
and biased fast neutron calculation in SERA. The best agreement with SERA is obtained if
the F6 energy deposit tally is applied for the Dg calculations in the MCNP and the source
models are normalized according to the FiR 1 protocol.
The SERA comparison studies show that the dose calculation accuracy can be considered
sufficient for reliable BNCT dose planning with ASDs from 0 to 5 cm, despite slight
overestimation of the epithermal and underestimation of the thermal neutrons in the beam
model, and miscalculation of the dose on the surface. Moreover, the dose calculation with
the MCNP code and the JCDS system is very similar to that of SERA. Since both codes
have similar accuracy in comparison to measurements, MCNP can be applied as a
reference calculation method at the FiR 1 beam.
In these studies, the neutron doses in MCNP were calculated, using the track length
estimate tally F4 with the tally multiplier card counting total heating in MeV per collision
61
for hydrogen, boron, and nitrogen. The photon doses were calculated with the F6 total
energy deposit tally or by applying flux-to-dose conversion factors from the 1977
ANSI/ANS. In SERA, the corresponding dose components were calculated from the
neutron and photon fluences by applying flux-to-dose conversion factors from the
MACLIB (ENDF-B/IV) library. If different dose calculation methods are applied in
MCNP, the agreement between the codes may differ from that observed in this thesis.
Limitation of SERA dose calculation verification is that the radial dose or fluence
distributions have not been compared in this thesis.
9.2 Photon dose
An alarming fact related to the discrepancy between the measured and calculated Dg at the
FiR 1 beam is that the difference increases with the phantom depth. An inaccurately
determined effective point of the Mg(Ar) chamber partially explained the increasing
difference (Koivunoro et al. 2011). With the 0.3 cm shift in the effective point, the
difference becomes smaller, but still increases with phantom depth (from 5% to 9%).
Measurements by the visiting research group from MIT, using C(CO2) IC, provided linear
deviation between the experimental and calculated Dg for  the  FiR  1  beam  in  the  water
phantom. The measurement results of the MIT team are published in Binns et al. (2005).
The C(CO2) measurement predicts 6–9% higher Dg values than the SERA and MCNP
calculations at depths up to 16 cm in the phantom. Agreement between the two ICs for Dg
is  from  -3%  to  1%  at  depths  up  to  10  cm,  except  that  at  the  most  shallow  measurement
point the C(CO2) chamber predicts an 8% higher dose.
Deviation between the measured and calculated Dg indicates that the FiR 1 photon beam
model may be inaccurately determined in terms of photon spectra or intensity. As
mentioned earlier, the photon beam model is not verified against measurements and the
same normalization factor (based on neutron activation measurements) as for the neutron
beam model was applied. However, in-air measurements with the C(CO2) and Mg(Ar)
chambers in the FiR 1 beam predict considerably higher Dg values (0.34–0.37 Gy/h) than
the MCNP calculations (0.20 Gy/h) (previously unpublished result). The beam model
verification can be performed through measurements of the photon spectrum with the
Mg(Ar) chamber applying multiple buildup caps with different thicknesses, as has been
reported for the Tsing Hua Open-Pool Reactor (THOR) BNCT facility in Taiwan (Liu et al.
2011).
The increasing discrepancy with phantom depth between the Dg calculations and
measurements may also indicate that the Mg(Ar) chamber signal is inaccurately
interpreted. Either the chamber response for the epithermal neutron beam is incorrectly
determined or the chamber is neutron-sensitive (unlike assumed). As mentioned earlier, the
chamber response for the FiR 1 beam should be determined through simulations of the real
measurement  situation  (discussed  in  the  next  section).  The  thermal  neutron  sensitivity  of
the chamber could be measured in a pure neutron beam, which can be created at the FiR 1
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mixed beam with a thick moderator of material, which absorbs but does not create photons
via neutron interactions. Thermal neutron sensitivity was reported previously for chambers
of the same type (Raaijmakers and Konijnenberg 1995). In addition, neutron activation of
the Mg(Ar) chamber structures caused 2% increase in the IC signal at the epithermal
neutron beam of the THOR reactor (Liu et al. 2010), which is not taken into account at the
FiR 1 beam.
9.3 IC response simulations
Munck af Rosenschöld et al. (2002) used MCNP version 4 for simulations of the Mg(Ar)
and TE(TE) chamber responses of photons in an epithermal neutron beam of the Studsvik
reactor in Sweden. The photon quality correction factors, which determine the chamber
response in an epithermal neutron beam relative to the reference 60Co beam, were
determined. One limitation of the study was that the calculation results were not compared
with experimental data or reference calculations. In the study by Roca et al. (2002), the
same chambers were modeled with the MCNPX code and their response was calculated
and measured in the 60Co reference beam. For the TE(TE) chamber, the difference between
the calculated and measured current inside the gas cavity were within 2%, whereas for the
Mg(Ar) chamber, MCNPX overestimated the dose by 7% in comparison to the
measurement. The authors suspected that the systematic discrepancy in the case of the
Mg(Ar) chamber was caused by overestimation of the chamber’s sensitive volume. In the
study by Munck af Rosenschöld et al. (2002), the electron transport algorithm applied was
not reported, whereas the ITS-based electron transport was applied in the study by Roca et
al. (2002).
Based on the results in Publication VI, the MCNP electron transport is not accurate enough
for IC response simulations in the clinical photon beams, since in conventional
radiotherapy, the IC response can be calculated with an accuracy of well below 1% using
the other codes. However, MCNP may still be a useful tool for improving the dose
determination accuracy in BNCT, since the calculation uncertainty (2% ± 1%) for
dosimetric gases and the energy range of BNCT is low, compared with the current
uncertainty of the IC measurements in the BNCT beam.
The TE(TE) chamber response simulations for neutron dose requires a simulation code,
that handles transport of various charged particles created in the neutron interactions. The
codes could include e. g. PHITS, MCNPX and GEANT4. So far, the neutron response has
been determined according to formalism presented by ICRU (ICRU 1989), based on gas-
to-wall conversion factors, the energy required to produce an ion pair by secondary charged
particles, and the neutron fluence-dependent KERMAs (ratio for tissue and chamber wall)
at the measurement points. The uncertainty of the relative sensitivity of the chamber for the
BNCT beam was estimated to be 10% (Kosunen et al. 1999), which could be improved by
the chamber response simulations. Since uncertainty in the neutron dose determination is
mostly due to subtraction of the photon dose measured with the Mg(Ar) chamber from the
total dose measured with the TE(TE) chamber, more accurate Mg(Ar) chamber
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measurements would already improve TE(TE) detector measurement accuracy
considerably.
9.4 Fusion neutron sources
The fusion neutron generator model and BSA system studied in Publication V would
presumably yield 1014 neutrons per second from D-T fusion, which should be a sufficient
number for clinical brain or liver cancer BNCT. This neutron generator model is not
adequate for clinical BNCT if the D-D fusion reaction is utilized (yield 1012 neutrons per
second). However, this theoretical study of neutron moderation has limitations. The more
realistic study by Durisi et al. (2007) for D-D neutron generators includes some space
between  the  neutron  source  and  BSA  and  an  electric  insulator.  With  this  realistic
configuration, the neutron fluence rate in the patient side is somewhat lower than in the
ideal configuration presented in the Publication V. A neutron generator utilizing the D-T
fusion reaction seems more realistic than D-D fusion, since almost two orders of magnitude
less power is required for sufficient neutron yield for BNCT application. However, with the
D-T fusion reaction some practical aspects need to be overcome. The neutron generators
developed at LBNL, which utilize D-D fusion, operate on an open system, so that
deuterium gas is constantly pumped out of the generator to maintain the fusion reaction. In
D-T fusion, the generator needs to be a sealed system, since tritium is a highly reactive
radioactive isotope and potentially dangerous, if inhaled or ingested. Another practical
issue may be activation of the BSA and the neutron source structures, due to high (14.1
MeV) initial neutron energy.
9.5 BNCT of liver
Results  of  Publication  V  show  that  a  tumor  dose  of  30  Gy  (W)  cannot  be  delivered
throughout the liver volume with the epithermal neutron beams and boron concentrations
studied. Since epithermal neutron penetration is limited, the entire liver treatment can be
achieved with BNCT only by enhancing the tumor-to-tissue boron concentration ratio.
With less or more energetic neutron beams, the skin dose would increase and thus limit the
treatment time. In the study, the boron concentrations were assumed to be similar to those
measured for the first liver cancer patient in Italy (Pinelli et al. 2002). In that case, the
BPA-fructose complex (300 mg/kg) was injected through the colic vein in 2 hours, which
led to a boron concentration ratio of 6:1 between the tumor and healthy liver at irradiation
time. The concentration ratio was clearly higher than that commonly assumed (3.5:1) for
the peripheral BPA-F infusion (Imahori et al. 1998, Kabalka et al. 1997, Ishiwata et al.
1992, Kato et al. 2004). A boron concentration ratio between tumor and healthy liver of
18:1 would be needed to cover nearly all of the liver volume with a greater than 30 Gy (W)
dose, if the boron concentration in healthy tissue were 8 (Publication V). It has been
suggested that boron could be administered to liver tumors more selectively, using
locoregional infusion via the hepatic artery (Zanon et al. 2001).
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Later on, a patient with multiple liver tumors received intra-arterial administration of BPA
and BSH, with a vessel-embolizing agent, lipiodol, directly via the right hepatic artery,
followed by neutron irradiation (Suzuki et al. 2007). The boron concentration of the blood
just before irradiation was 11.6 ppm and of liver 23.8 ppm estimated with the -telescope.
Recently, a 15:1 boron concentration ratio between liver tumor and healthy liver was
demonstrated in rabbits using intra-arterial administration of boron-entrapped water-in-oil-
in-water emulsion (Yanagie et al. 2011). Moreover, a cationized gelatin-hemagglutinating
virus of Japan (HVJ) envelope with BSH has shown a boron concentration ratio of up to
35:1 between liver tumor and healthy tissue in vivo (Fujii et al. 2011), while intravenous
and intraperitoneal injection of two boron carriers (BPA and GB-10) demonstrated a boron
concentration ratio between tumor and healthy liver of at most of 2.3  0.9 ppm
(Garabalino et al. 2010). The authors, however, hypothesized that preferential uptake of the
boron compound by tumor tissue may not be as essential to BNCT success as previously
reported. The Argentinian research group showed in small animal studies that in BNCT
mediated  by  the  chemically  non-selective  boron  compound  GB-10,  selective  tumor
lethality results from tumor blood vessel damage rather than from selective tumor uptake,
since GB-10-BNCT selectively damages tumor vessels, sparing precancerous and normal
tissue vessels (Trivillin et al. 2006). GB-10, a stable polyhedral borane dianion, used in the
second Brookhaven GBM clinical trial in 1961, has no targeting features, is of low toxicity
even at high concentrations, and is commercially available under investigational new drug
(IND) status in the US (Hawthorne and Lee 2003).
The advantageous of BNCT over external photon radiotherapy in liver cancer is that, as a
biologically targeted treatment modality, BNCT should treat both visible and undetectable
tumors. The demand for a minimum 30 Gy (W) tumor dose throughout the liver may be
unnecessary, since BNCT doses to tumor may be more effective than calculated doses
indicate. Complete treatment responses have been achieved with calculated tumor doses as
low as 12–14 Gy (W) given twice (32–76 days apart) for HN cancer patients
(Kankaanranta et al. 2007, 2011). According to Publication V, high BNCT doses (up to 70
Gy (W)) can be delivered to liver tumors located at shallow depths from the skin, while the
minimum tumor dose in liver would be about 11 Gy (W) using an epithermal neutron
beam.
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10 Conclusions
In  this  thesis,  BNCT  dose  calculation  with  the  SERA  system  was  evaluated  against
reference dose calculation methods and measurements in various geometries (Publications
II–IV). The minimum phantom dimensions for undisturbed neutron and photon dose
measurements at the reference measurement depth and at every measurement point were
determined with MC simulations (Publication I). The accuracy of the MCNP5 code for IC
response simulations was determined (Publication VI). The suitability of compact fusion
reaction-based neutron generators for liver BNCT was evaluated (Publication V). The
calculated dose distributions from the fusion neutron sources and the FiR 1 beam were
compared (Section 8.2).
The multi-energy group representation of the nuclear interaction cross-sections applied in
SERA correlates  well  with  the  continuous  cross-sections  of  the  reference  code  MCNP in
the main energy range of an epithermal neutron beam. The neutron capture cross-section
for hydrogen is overestimated in SERA at < 1 eV in comparison to MCNP, which may lead
into higher photon dose, while the elastic scattering cross-sections are lower for the main
tissue elements (1H, 12C, 14N, 16O) and 10B below 10-2 eV or  10-3 eV energy,  which  may
cause overestimation of neutron fluence and dose.
The dose calculations with the SERA system are accurate against reference calculations for
the thermal neutron-induced dose components (DB, DN and Dg), which produce 99% of the
tumor dose and > 90% of the healthy tissue dose at points of relevance for treatment at the
FiR 1 facility. For these dose components, the deviation between SERA and the reference
calculations is within 4% in the phantoms and in a brain cancer patient model elsewhere,
except on the phantom or skin surface. The SERA calculations for the thermal neutron
fluence are accurate (within 5%) in comparison to the activation foil measurements. Large
(> 5%) deviation is found between the measured and calculated photon dose, which
produces from 25% up to > 50% of the healthy tissue dose at certain depths. The erratic
biased fast neutron run option in the SERA system leads in significant underestimation (up
to 30–60%) of the fast neutron dose. Currently, no reliable measurement method exists for
fast neutron detection of the FiR 1 beam, since the measurement accuracy is > 30%, due to
low fast neutron contamination.
For  the  FiR  1  neutron  beam,  the  minimum  reference  phantom  size  is  a  40  cm  ×  40  cm
cross-section and 20 cm depth, wherein the undisturbed measurements are achieved at the
reference depth (2 cm) for the neutron and photon dose components. A water scanning
phantom of size 56 cm × 56 cm cross-section and 28 cm depth is required for undisturbed
measurements of the depth and transverse profiles up to 5% isodose of the total dose.
The  MCNP5  code  is  applicable  for  the  IC  response  simulations  (with  accuracy  of  2% 
1%) in  BNCT dosimetry.  Nevertheless,  the  electron  transport  models  of  MCNP5 are  not
accurate enough for IC response simulations in conventional radiotherapy applications,
where better accuracy is required and can be achieved with the other codes.
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The D-D and D-T fusion-based neutron generators may be applicable for BNCT
treatments, if yields of > 1013 neutrons per second from D-D or D-T fusion can be obtained.
The simulations indicate that noninvasive BNCT of liver tumors is a technically possible
treatment  with  epithermal  neutron  beams,  while  the  30  Gy  (W)  tumor  dose  cannot  be
delivered at the deepest parts of the liver, if accumulation of boron in the tumor compared
with the healthy liver is sixfold or less.
The patient dose calculation practice is accurate, compared with reference calculation
methods for the major dose components induced by thermal neutrons in the FiR 1 beam.
Calculation of the thermal neutron fluence, which creates the most crucial patient dose, is
also  accurate  against  experimental  data.  Final  verification  of  the  fast  neutron  and  photon
dose calculation is restricted to high uncertainties in the existing measurement methods.
Determination  accuracy  of  the  absorbed  patient  dose  at  FiR  1  cannot  be  substantially
improved by focusing on measurement and calculation methods, since the most crucial
inaccuracy is due to inability to define exact boron distribution in the tumor and healthy
tissues during treatment. The earlier conclusions and the results of this thesis on the matter
confirm the statement.
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